Patent Grant
7833147
The present invention generally relates to the enrichment of a population of sperm cells. In particular, the present invention generally relates to the enrichment of a population of viable sperm cells without physically sorting the cells.
The fertilization of animals by artificial insemination (AI) and embryo transplant following in vitro fertilization is an established practice. In the livestock production industry, the ability to influence the reproductive outcome toward offspring having one or more desired characteristics has obvious advantages. By way of example, there would be an economic benefit in the dairy industry to preselect offspring in favor of the female sex to ensure the production of dairy cows. The separation of sperm into enriched populations of X and Y chromosome-bearing cells, known as gender enriched semen or gender enriched sperm, is one method of achieving preselected offspring.
Johnson et al. (U.S. Pat. No. 5,135,759) describe the separation of intact X and Y chromosome-bearing sperm populations according to DNA content using a flow cytometer/cell sorter into X and Y chromosome-bearing sperm enriched populations. As described, the sperm is combined with a DNA selective dye at a temperature of 30° C. to 39° C. for a period of 1 hour (39° C.) to 1.5 hours (30° C.). A flow cytometer is then used to measure the amount of fluorescent light given off when the sperm passes through a laser beam. Because the X chromosome-bearing sperm contains more DNA than the Y chromosome-bearing sperm, approximately 3% to 5% depending upon the species, the X chromosome-bearing sperm yields a greater intensity of fluorescent light than the Y chromosome-bearing sperm. Droplets containing single sperm of a predetermined fluorescent intensity are given a charge and electrostatically deflected into collection vessels. The collected, gender enriched sperm population, is then used for microinjection or artificial insemination. Notably, this method requires that the sperm cells be physically sorted to achieve the gender enriched sperm population. Physically sorting according to Johnson requires time and cost.
Among the various aspects of the present invention is a process for the preparation of sperm dispersions, sometimes referred to as suspensions, enriched with respect to a characteristic. In one embodiment, for example, the process of the present invention is used to prepare a sperm dispersion enriched with respect to X or Y-chromosome bearing sperm.
Briefly, therefore, the present invention is directed to a process for selectively decreasing the capacity of a subpopulation of sperm cells in a sperm cell dispersion to fertilize an egg. The process comprises forming a dispersion of labeled sperm cells in a liquid comprising a chemical agent or having a temperature that induces sperm immotility, wherein the presence, absence or amount of the label associated with a sperm cell indicates a genetic, proteomic, structural, or functional characteristic of a subpopulation of sperm cells in the dispersion. The process additionally comprises optically inspecting the dispersion to identify individual sperm cells as members of the subpopulation; determining the position of members of the subpopulation in the dispersion; and delivering a dose of energy to different positions within the dispersion to selectively decrease the capacity of members of the subpopulation to fertilize an egg without similarly affecting sperm cells at other positions in the dispersion.
The present invention is further directed to a process for inseminating a female mammal with an enriched sperm cell population. The process comprises forming a dispersion of labeled sperm cells in a liquid comprising a chemical agent or having a temperature that induces sperm immotility wherein the presence, absence or amount of the label associated with a sperm cell indicates a genetic, proteomic, structural, or functional characteristic of a subpopulation of sperm cells in the dispersion. The process further comprises optically inspecting the dispersion to identify individual sperm cells as members of the subpopulation; determining the position of members of the subpopulation in the dispersion; delivering a dose of energy to different positions within the dispersion to selectively decrease the capacity of members of the subpopulation to fertilize an egg without similarly affecting sperm cells at other positions in the dispersion; and thereafter inseminating a female mammal with the dispersion or a derivative thereof.
The present invention is further directed to a process for in vitro fertilization. The process comprises forming a dispersion of labeled sperm cells in a liquid comprising a chemical agent or having a temperature that induces sperm immotility wherein the presence, absence or amount of the label associated with a sperm cell indicates a genetic, proteomic, structural, or functional characteristic of a subpopulation of sperm cells in the dispersion. The process further comprises optically inspecting the dispersion to identify individual sperm cells as members of the subpopulation; determining the position of members of the subpopulation in the dispersion; delivering a dose of energy to different positions within the dispersion to selectively decrease the capacity of members of the subpopulation to fertilize an egg without similarly affecting sperm cells at other positions in the dispersion; and thereafter fertilizing an egg, in vitro, using the dispersion or a derivative thereof. The fertilized egg may thereafter be introduced into the uterus of a female mammal.
The present invention is further directed to a process for forming a frozen sperm dispersion. The process comprises forming a dispersion of labeled sperm cells in a liquid comprising a chemical agent or having a temperature that induces sperm immotility wherein the presence, absence or amount of the label associated with a sperm cell indicates a genetic, proteomic, structural, or functional characteristic of a subpopulation of sperm cells in the dispersion. The process further comprises optically inspecting the dispersion to identify individual sperm cells as members of the subpopulation; determining the position of members of the subpopulation in the dispersion; delivering a dose of energy to different positions within the dispersion to selectively decrease the capacity of members of the subpopulation to fertilize an egg without similarly affecting sperm cells at other positions in the dispersion; and thereafter cryopreserving the dispersion.
Other aspects and features of the invention will be in part apparent and in part pointed out hereinafter.
Advantageously, a population of viable sperm cells may be enriched with respect to a characteristic in accordance with the present invention without physically sorting the cells. This characteristic may be, for example, whether the sperm cells carry an X or a Y chromosome. Alternatively, the characteristic may be another genetic characteristic such as the presence of a single nucleotide polymorphism (“SNP”) coding for improved animal productivity (such as, for example, improved milk production) or coding for a lipid to improve cryopreservation of the selected cells. The characteristic may also be a proteomic characteristic such as a protein to improve the performance of sperm, such as, for example, a protein that would improve in utero performance by improving beneficial acrosomal characteristics. The characteristic may also be a structural characteristic, such as, for example, acrosomal integrity, or a functional characteristic, such as, for example, progressive motility.
Enrichment of a sperm cell population with respect to the genetic, proteomic, structural, or functional characteristic may be achieved, for example, by labeling sperm cells in the population having (or, alternatively, lacking) the characteristic, rendering the sperm cells substantially immotile, and selectively dosing the immotile sperm cells with a dose of energy to decrease the viability of the dosed cells or at least decrease the capacity of the dosed cells to fertilize an egg in vitro or in vivo (i.e., after insemination). Because the sperm cells in the dispersion, sometimes referred to as a suspension, are substantially immotile and selectively labeled, the energy beam may be delivered to a specific position in the dispersion to dose an individual sperm cell; by repeating this process step, i.e., individually dosing immotile sperm cells at discrete positions in the dispersion, a subpopulation of sperm cells having a desired characteristic in the dispersion may be effectively enriched, for example, with respect to the percentage of cells of the subpopulation having the desired characteristic; with respect to the percentage of offspring having a certain genetic or proteomic characteristic as a result of being produced by fertilization with the sperm cells; or with respect to both.
In any event, the population of sperm cells may be enriched for a particular subpopulation without physically separating cells having the desired characteristic from those lacking the desired characteristic (i.e., without separating the dosed cells from the non-dosed cells). Optionally, further enrichment of the cells may be achieved by additionally purifying the cells by physically separating the dosed and non-dosed cells into separate subpopulations according to methods described below.
Sperm Cell Dispersion
Density of the Sperm Cells
In general, sperm cell dispersions having a population that may be enriched in some characteristic may be prepared with a wide range of sperm cell densities. Typically, however, the sperm cell density will be at least about 1×103 sperm/ml, and generally not in excess of about 5×1010 sperm/ml, and more preferably not in excess of about 5×108 sperm/ml of dispersion. For example, in one embodiment the dispersions may contain spermatozoa in a “relatively low” density, i.e., in a density of less than about 1×107 sperm/ml, preferably less than about 1×106 sperm/ml, more preferably about 1×103 to about 5×106 sperm/ml, still more preferably about 1×103 to about 1×106 sperm/ml, even more preferably about 1×104 to about 1×105 sperm/ml, and most preferably about 1×105 sperm/ml of dispersion. In an alternative embodiment, the dispersions may contain spermatozoa in an “intermediate” density, i.e., in a density of about 1×107 to about 1×108 sperm/ml of dispersion. In yet another alternative embodiment, the dispersions may contain spermatozoa in a “relatively high” density, i.e., in a density of at least about 1×108 sperm/ml, preferably about 1×108 to about 5×1010 sperm/ml, more preferably about 1.5×108 to about 2×1010 sperm/ml, even more preferably about 1.5×108 to about 2×108 sperm/ml, and still more preferably about 1.5×108 sperm/ml of dispersion. Thus, for example, the dispersions may contain at least about 0.04×106 sperm/ml of dispersion in one embodiment; at least about 1×106 in another embodiment; at least about 1.5×106 in another embodiment; at least about 2×106 in another embodiment; at least about 3×106 in another embodiment; at least about 0.5×107 in another embodiment; at least about 1×107 in another embodiment; at least about 1.25×107 in another embodiment; at least about 2×107 in another embodiment; at least about 3×107 in another embodiment; at least about 4×107 in another embodiment; at least about 5×107 in another embodiment; at least about 6×107 in another embodiment; at least about 7.0×107 in another embodiment; at least about 8×107 in another embodiment; at least about 9×107 in another embodiment; at least about 10×107 in another embodiment; at least about 11×107 in another embodiment; at least about 12×107 in another embodiment; at least about 1.0×108 in another embodiment; at least about 1.25×108 in another embodiment; at least about 1.5×108 in another embodiment; at least about 1.75×108 in another embodiment; at least about 2.0×108 in another embodiment; at least about 2.25×108 in another embodiment; at least about 2.5×108 in another embodiment; at least about 2.75×108 in another embodiment; at least about 3×108 in another embodiment; at least about 5×108 in another embodiment; at least about 7.0×108 in another embodiment; or even at least about 8×108 sperm/ml of dispersion. In an alternative embodiment, the dispersion may contain less than about 9×105, less than about 7×105, less than about 5×105, less than about 2×105, less than about 1×105, less than about 1×104, or even less than about 1×103 sperm/ml of dispersion.
The density of spermatozoa may vary based upon a number of factors, including, for example, the variations among different species of mammals, variations among the mammals of a single species, and even variations among different ejaculates of a single mammal. For example, bovine spermatozoa may be in a dispersion at a higher density, but typically in a smaller volume, such as for example 0.5×106 sperm/ml to about 8×107 sperm/ml in a volume of about 0.5 ml to about 25 ml. Swine spermatozoa, however, may be in a dispersion at a lower density, but typically in a greater volume, such as for example 0.04×106 sperm/ml to about 1×107 sperm/ml in a volume of about 50 ml to about 250 ml.
The density of spermatozoa in the sperm dispersions may also depend upon the method by which the sperm cells may be subsequently enriched or sorted. For example, the sperm cells may be sorted using flow cytometry as described in U.S. Patent Application Publication No. US 2005/0112541, the content of which is hereby incorporated herein by reference. In such an instance, the dispersion may typically be of an “intermediate” or “relatively high” density of spermatozoa. Other sorting or enrichment techniques, as described in greater detail below, may benefit from a lesser density of spermatozoa, such as a “relatively low” density of spermatozoa, labeled with a marker, such as for example the dyes and labels described herein.
The density of the spermatozoa in the sperm dispersions may also be artificially manipulated to achieve a dispersion of a specific spermatozoa density. Manipulations to the density of spermatozoa in a sperm dispersion, for example, contained in an insemination straw, may be made based upon factors such as the temperature at which the dispersion may be stored, the length of the storage period, whether the spermatozoa in the sperm dispersion are sorted or unsorted, the species of the male mammal from which the spermatozoa were collected, the fertility of the mammal from which the spermatozoa were collected, and the species of the female mammal to be inseminated.
The density of the spermatozoa in a sperm dispersion may also be affected by simply concentrating the spermatozoa, such as for example, by centrifugation. In such an instance, the dispersion would substantially separate into what is commonly referred to as a pellet (a mass of cells containing a minimal amount of fluid) and a supernatant (a soluble liquid fraction). The supernatant may then be decanted without disruption of the pellet, thereby resulting in a relatively dense pellet of sperm cells containing a minimal amount of the inhibitor, the effect being to reduce the volume of the dispersion without changing the components of the dispersion. As a result, the sperm cells of the pellet remain in an immotile state.
Immotility of the Sperm Cells
The dispersion of sperm cells contains sperm cells that have a substantially reduced motility. Substantial reduction of the motility of the sperm cells in the sperm cell dispersion may be achieved in a number of ways, including for example, by contacting the sperm cells with a motility inhibitor, by reducing the temperature of the sperm cells or the immediate environment surrounding the sperm cells (i.e., the sperm dispersion), or by a combination of both. In a preferred embodiment, sperm cells in the sperm dispersion of the present invention behave, in certain respects, in a manner characteristic of epididymal spermatozoa; for example, the sperm cells in the population are substantially immotile and/or they may have a lesser rate of endogenous respiration as compared to washed or freshly ejaculated spermatozoa. Advantageously, the immotile sperm cells, sometimes referred to as quiescent sperm cells, have the ability, upon separation from the inhibitor(s) or exposure to an increase in temperature, to behave in a manner characteristic of ejaculated spermatozoa (and not characteristic of epididymal spermatozoa) with respect to motility and, in one embodiment, with respect to motility and respiration.
In one embodiment, for example, the inhibitor, the reduction in temperature, or a combination of both reduces path velocity (sometimes referred to as motility or path motility), progressive velocity (sometimes referred to as progressive motility), or both, as measured by HTM-IVOS sperm analysis (Hamilton-Thorne HTM-IVOS computer assisted sperm analysis system Hamilton-Thorne Research, Beverly Mass.) of at least about 50% of the sperm cells in the dispersion relative to the path velocity, progressive velocity, or both of sperm cells in a fresh ejaculate of the same species. Preferably, the motility inhibitor, the reduction in temperature, or a combination of both reduces path velocity, progressive velocity, or both, as measured by HTM-IVOS sperm analysis, of at least about 60% of the sperm cells in the dispersion relative to the path velocity, progressive velocity, or both of sperm cells in a fresh ejaculate of the same species. More preferably, the motility inhibitor, the reduction in temperature, or a combination of both reduces path velocity, progressive velocity, or both, as measured by HTM-IVOS sperm analysis, of at least about 70% of the sperm cells in the dispersion relative to the path velocity, progressive velocity, or both of sperm cells in a fresh ejaculate of the same species. Still more preferably, the motility inhibitor, the reduction in temperature, or a combination of both reduces path velocity, progressive velocity, or both, as measured by HTM-IVOS sperm analysis, of at least about 80% of the sperm cells in the dispersion relative to the path velocity, progressive velocity, or both of sperm cells in a fresh ejaculate of the same species. Even more preferably, the motility inhibitor, the reduction in temperature, or a combination of both reduces path velocity, progressive velocity, or both, as measured by HTM-IVOS sperm analysis, of at least about 90% of the sperm cells in the dispersion relative to the path velocity, progressive velocity, or both of sperm cells in a fresh ejaculate of the same species. Even more preferably, the motility inhibitor, the reduction in temperature, or a combination of both reduces path velocity, progressive velocity, or both, as measured by HTM-IVOS sperm analysis, of at least about 95% of the sperm cells in the dispersion relative to the path velocity, progressive velocity, or both of sperm cells in a fresh ejaculate of the same species. Most preferably, the motility inhibitor reduces path velocity, progressive velocity, or both, as measured by an HTM-IVOS sperm analysis, of at least about 99% of the sperm cells in the dispersion relative to the path velocity, progressive velocity, or both of sperm cells in a fresh ejaculate of the same species.
A motility inhibitor may be used to substantially reduce the motility of the sperm cells in the sperm cell dispersion. The inhibitor may be any of a range of compositions having a depressive effect upon sperm motility. Such compositions include, for example, sodium channel inhibitors, such as, ouabain; compositions comprising potassium ions; and compositions comprising potassium and sodium ions. For example, relatively high concentrations of potassium ions in the dispersion tend to depress sperm motility. In general, therefore, it is preferred that the dispersion contain a source of potassium ions and that the potassium concentration in the dispersion be at least about 0.05 moles/L. More preferably, the potassium concentration is at least about 0.05 moles/L to about 0.5 moles/L. Still more preferably, the potassium concentration is at least about 0.1 moles/L to about 0.3 moles/L. Most preferably, the potassium concentration is at about 0.173 moles/L. Such dispersions will typically, but not necessarily, also contain a source of sodium ions. When sodium is present, the molar ratio of potassium to sodium is generally equal to or greater than 1:1, respectively, but will generally not exceed a molar ratio of 8:1. Preferably, the molar ratio of potassium to sodium is at least about 1.25:1. Still more preferably, the molar ratio of potassium to sodium is at least about 1.5:1. Still more preferably, the molar ratio of potassium to sodium is at least about 1.75:1. Still more preferably, the molar ratio of potassium to sodium is at least about 1.78:1. In one particular embodiment, the molar ratio of potassium to sodium is at least about 2:1. In yet another embodiment, the molar ratio of potassium to sodium is at least about 3:1. In still another embodiment, the molar ratio of potassium to sodium is at least about 4:1. In still another embodiment, the molar ratio of potassium to sodium is at least about 5:1. In still another embodiment, the molar ratio of potassium to sodium is at least about 6:1. In still another embodiment, the molar ratio of potassium to sodium is at least about 7:1. In still another embodiment, the molar ratio of potassium to sodium is at least about 8:1.
The sperm dispersion may additionally comprise an ion or source of carbon dioxide capable of enhancing the down-regulation of motility. In this embodiment, the source of carbon dioxide may be, for example, one or more carbonates. In one presently preferred embodiment, the sperm dispersion comprises NaHCO3 and KHCO3, thereby providing a source of potassium and sodium ions as well as an increased partial pressure of carbon dioxide (relative to the ambient atmosphere). For example, in one presently preferred embodiment, the dispersion comprises NaHCO3 and KHCO3 in an aqueous solution, preferably NaHCO3, KHCO3, and C6H8O7.H2O in water; in general, the KHCO3 concentration in the dispersion may be at least about 0.05 moles/L. More preferably, the KHCO3 concentration is at least about 0.05 moles/L to about 0.5 moles/L. Still more preferably, the KHCO3 concentration is at least about 0.1 moles/L to about 0.3 moles/L. In one particularly preferred embodiment, the dispersion is formed using an motility inhibitor comprising 0.097 moles/L of NaHCO3, 0.173 moles/L of KHCO3, 0.090 moles/L C6H8O7.H2O in water as disclosed in Salisbury & Graves, J. Reprod. Fertil., 6:351-359 (1963). The sperm cells will generally remain quiescent as long as they are exposed to the motility inhibitor(s).
When C6H8O7.H2O is present in the dispersion, the molar ratio of KHCO3 to NaHCO3 may be as described above. The molar ratio of KHCO3 to C6H8O7.H2O may generally be equal to or greater than 1:1, respectively, but will generally not exceed a molar ratio of 8:1. Preferably, the molar ratio of KHCO3 to C6H8O7.H2O is from at least about 1.25:1. Still more preferably, the molar ratio of KHCO3 to C6H8O7.H2O is at least about 1.5:1. Still more preferably, the molar ratio of KHCO3 to C6H8O7.H2O is at least about 1.75:1. In one particular embodiment, the molar ratio of KHCO3 to C6H8O7.H2O is at least about 1.78:1. In another particular embodiment, the molar ratio of KHCO3 to C6H8O7.H2O is at least about 2:1. In yet another embodiment, the molar ratio of KHCO3 to C6H8O7.H2O is at least about 3:1. In still another embodiment, the molar ratio of KHCO3 to C6H8O7.H2O is at least about 4:1. In still another embodiment, the molar ratio of KHCO3 to C6H8O7.H2O is at least about 5:1. In still another embodiment, the molar ratio of KHCO3 to C6H8O7.H2O is at least about 6:1. In still another embodiment, the molar ratio of KHCO3 to C6H8O7.H2O is at least about 7:1. In still another embodiment, the molar ratio of KHCO3 to C6H8O7.H2O is at least about 8:1. In one particularly preferred embodiment, the dispersion is formed using an inhibitory buffer comprising 0.097 moles/L of NaHCO3, 0.173 moles/L of KHCO3, 0.090 moles/L C6H8O7.H2O in water as disclosed in Salisbury & Graves, J. Reprod. Fertil., 6:351-359 (1963). The sperm cells will generally remain quiescent as long as they are exposed to the motility inhibitor(s).
Experimental evidence to date further suggests that the overall health and other vital characteristics of sperm cells may be improved if the sperm dispersion is maintained under an atmosphere that reduces or prevents the diffusion of oxygen into the dispersion. This can be achieved by replacing the atmosphere of gas above the sperm dispersion with an atmosphere having an enhanced partial pressure of, for example, carbon dioxide, nitrogen, or other inert gases relative to ambient air. In a particular embodiment, the dispersion is maintained under an atmosphere having an enhanced partial pressure of carbon dioxide relative to air. In a preferred embodiment, the atmosphere over the dispersion has a partial pressure of carbon dioxide of at least about 0.0001 atm, but generally less than about 5 atm at atmospheric pressure. In one embodiment, the partial pressure of carbon dioxide is about 0.5 atm to about 2 atm at atmospheric pressure; in another embodiment, the partial pressure of carbon dioxide is about 0.9 atm to about 2 atm at atmospheric pressure; in another embodiment, the partial pressure of carbon dioxide is about 0.95 atm to about 2 atm at atmospheric pressure. In a particularly preferred embodiment, the atmosphere over the dispersion has a partial pressure of carbon dioxide of at least 0.9 atm; more preferably, at least about 0.95 atm.
Alternatively, or in addition to the use of a motility inhibitor, the temperature of the sperm cells or the dispersion may be altered in order to induce the sperm cells to become immotile. The temperature induced sperm immotility may be induced, for example, by reducing the temperature of the sperm cells or the dispersion to about 0° C. to about 15° C., preferably from about 1° C. to about 10° C.; more preferably from about 2° C. to about 8° C., still more preferably from about 3° C. to about 6° C., and even more preferably from about 4° C. to about 5° C., and still more preferably about 5° C. Preferably, however, the sperm cells are not exposed to temperatures that substantially detrimentally affect the viability of the cells or significantly affect the ability of the sperm cells to bind or uptake a label.
In another embodiment, the temperature of the sperm cells or the sperm dispersion may be altered such that the sperm cells or the sperm dispersion may be at a temperature within the range of about 4° C. to about 50° C.; preferably from about 7° C. to about 43° C.; more preferably from about 10° C. to about 39° C.; still more preferably from about 15° C. to about 30° C.; and most preferably from about 17° C. to about 25° C. In a particularly preferred embodiment, the temperature of the sperm cells or the surrounding dispersion may be about 4° C.
The sperm cells may be exposed to the reduced temperature, and thereby rendered substantially immotile, at any time once the cells have been obtained from the source mammal. For example, the temperature of the sperm cells may be reduced, thereby inducing sperm immotility, upon collection of the cells from the source mammal, upon combining the cells with a buffer, upon formation of the labeling mixture, including before, during, or after the labeling process, or upon formation of the dispersion of labeled cells. Generally, however, sperm immotility may be induced by a reduction in temperature prior to the optical inspection of the dispersion.
For example, the temperature of the sperm cells may be reduced (i.e., sperm immotility may be induced) subsequent to labeling of the cells, thereby allowing for labeling to occur at a more preferred temperature as discussed below. In a preferred embodiment, the temperature of the sperm cells or surrounding dispersion may be reduced (i.e., sperm immotility may be induced) subsequent to labeling and prior to optical inspection of the cells.
Exposure of the sperm cells to the inhibitor, to the reduced temperature, or to a combination of both induces the sperm cells to become immotile. In one embodiment, for example, the motility inhibitor, the reduction in temperature, or a combination of both reduces the motility, progressive motility, or both of at least 60% of the sperm cells in the dispersion relative to the motility, progressive motility, or both of sperm cells in a fresh ejaculate of the same species. Preferably, the motility inhibitor, the reduction in temperature, or a combination of both reduces the motility, progressive motility, or both of at least 70% of the sperm cells in the dispersion relative to the motility, progressive motility, or both of sperm cells in a fresh ejaculate of the same species. More preferably, the motility inhibitor, the reduction in temperature, or a combination of both reduces the motility, progressive motility, or both of at least 80% of the sperm cells in the dispersion relative to the motility, progressive motility, or both of sperm cells in a fresh ejaculate of the same species. Preferably, the motility inhibitor, the reduction in temperature, or a combination of both reduces the motility, progressive motility, or both of at least 90% of the sperm cells in the dispersion relative to the motility, progressive motility, or both of sperm cells in a fresh ejaculate of the same species. Preferably, the motility inhibitor, the reduction in temperature, or a combination of both reduces the motility, progressive motility, or both of at least 99% of the sperm cells in the dispersion relative to the motility, progressive motility, or both of sperm cells in a fresh ejaculate of the same species.
The cells are preferably rendered immotile, regardless of the method used, for a time sufficient to allow for the optical inspection of the dispersion, the determination of the position of the member cells of the subpopulation; and the dosing of the member cells of the subpopulation with an energy source. If it is desired to physically separate the dosed from the non-dosed cells, it may also be preferred to maintain the sperm cells in an immotile state through this process step. Similarly, if the sperm cells are to be cryopreserved, they may be maintained in an immotile state through the cryopreservation step (independent of whether the dosed cells are physically separated from the non-dosed cells prior to cryopreservation). In a preferred embodiment, the cells are kept immotile through the step of cryopreservation.
Immotile cells may be returned to an active state, i.e., behavior characteristic of fresh ejaculate, by separating the cells from the motility inhibitor, exposing them to air, increasing the temperature of the cells or cell dispersion (preferably to the typical temperature of freshly ejaculated spermatozoa), by dilution with physiological saline (Salisbury et al., 1963) or a buffer such as a TCA buffer or PBS, or by any combination of the above, depending upon, for example, the method used to induce immotility. Typically, at least about 20%, preferably at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, even more preferably at least about 80%, even more preferably at least about 90%, still more preferably at least about 95%, and most preferably at least about 99% of the cells returned to an active state (i.e., reactivated cells) will have a path velocity, progressive velocity, or both, as measured by HTM-IVOS sperm analysis, that is at least about 50%, preferably at least about 60%, more preferably at least about 70%, still more preferably at least about 80%, even more preferably at least about 90%, even more preferably at least about 95%, and most preferably at least about 99% of the path velocity, progressive velocity, or both of the sperm cells prior to being combined with the motility inhibitor (i.e., of sperm cells of a fresh ejaculate).
Collection of the Cells from a Mammal
Various methods of collection of viable sperm are known. Such methods include, for example, the gloved-hand method, use of an artificial vagina, and electro-ejaculation.
At the time of collection, or subsequently, the collected sperm may be combined with any of a number of various buffers that are compatible with sperm, such as TCA, HEPES, PBS, or any of the other buffers disclosed in U.S. Patent Application Publication No. US 2005/0003472, the content of which is hereby incorporated herein by reference. For example, a bovine semen sample typically containing about 0.5 to about 10 billion sperm cells per milliliter may be collected directly from the source mammal into a vessel containing a buffer to form a sperm suspension. Alternatively, the semen sample may be collected into an empty vessel and then subsequently contacted with a buffer within several minutes to hours after collection to form the sperm suspension.
Alternatively, the sperm cells may be collected and contacted with a motility inhibitor in lieu of or in addition to a buffer, thereby forming a sperm dispersion. The sperm cells may be collected directly from the animal into a vessel containing a motility inhibitor to form the sperm dispersion, or alternatively, may be collected into an empty vessel and then subsequently combined with a motility inhibitor within several minutes (or even hours) of collection to form the sperm dispersion.
The sperm dispersion may also contain a range of other additives to enhance sperm viability. Exemplary additives include protein sources, antibiotics, growth factors, and compositions that regulate oxidation/reduction reactions intracellularly and/or extracellularly. Examples of each of these additives are well known in the art, as demonstrated in the disclosure of, for example, U.S. Application Ser. Nos. 60/557,407 and 11/092,313, the content of each of which is hereby incorporated herein by reference.
Labeling of the Cells
Sperm cells may be labeled with any of a number of different labels, including labels that bind to the exterior of the cell (such as, for example, fluorescently labeled antibodies) as well as labels that cross the cell membrane and bind to the internal contents of the cell (such as, for example, fluorescent DNA selective dyes). Generally, the labeling process comprises contacting the sperm cells with a concentration of label (thereby forming a labeling mixture, sometimes referred to as a staining mixture), at a temperature and pH that allow for rapid and efficient binding or uptake of the label, for a time sufficiently long to obtain the desired degree of labeling, without substantially affecting the viability of the cells.
The sperm may be in the form of neat semen, or alternatively, a sperm-containing semen derivative obtained by centrifugation or the use of other means to separate semen into fractions. The sperm cells are then contacted or otherwise combined with the label to form a labeling mixture; optionally, the label may be in the form of a solid or a solution. Generally, however, the label, the sperm cells, or both are in a medium such as a buffer.
In one embodiment, the sperm cells are combined with a buffer to form a sperm suspension. Any of a number of various buffers that are compatible with sperm, such as for example, TCA, HEPES, PBS, or the buffers disclosed in U.S. Patent Application Publication No. US 2005/0003472 may be used. Once formed, the sperm suspension may be combined with a source of label to form a labeling mixture; optionally, the label may be in solid or liquid form and, as a further option, may additionally comprise any of the previously mentioned buffers.
In another embodiment, the label is combined with a buffer to form a labeling suspension and the labeling suspension is combined with a sperm source in the form of neat semen, a sperm-containing semen derivative, or a sperm suspension to form the labeling mixture.
In a preferred embodiment, a buffer comprising a motility inhibitor is used to form the labeling mixture. For example, the motility inhibitor may be included in the buffer used to form a sperm suspension (which is then combined with the label) or a labeling suspension (which is then combined with a source of sperm) to form the labeling mixture. In either event, the result is a sperm dispersion containing a motility inhibitor and label.
The labeling mixture may be formed by using any of a number of labels, such as for example, one or more UV or visible light excitable, DNA selective dyes, as previously described in U.S. Pat. No. 5,135,759 and WO 02/41906, each of which is hereby incorporated herein by reference. Exemplary UV light excitable, DNA selective dyes include Hoechst 33342 and Hoechst 33258, each of which is commercially available from Sigma-Aldrich (St. Louis, Mo.). Exemplary visible light excitable dyes include SYBR-14, commercially available from Molecular Probes, Inc. (Eugene, Oreg.) and bisbenzimide-BODIPY® conjugate 6-{[3-((2Z)-2-{[1-(difluoroboryl)-3,5-dimethyl-1H-pyrrol-2-yl]methylene}-2H-pyrrol-5-yl)propanoyl]amino}-N-[3-(methyl{3-[({4-[6-(4-methylpiperazin-1-yl)-1H,3′H-2,5′-bibenzimidazol-2′-yl]phenoxy}acetyl)amino]propyl}amino)-propyl]hexanamide (“BBC”) described in WO 02/41906. Each of these dyes may be used alone or in combination; alternatively, other cell permeant UV and visible light excitable dyes may be used, alone or in combination with the aforementioned dyes, provided the dye does not detrimentally affect the viability of the sperm cells to an unacceptable degree when used in concentrations which enable sorting as described elsewhere.
Alternatively, the labeling mixture may be formed using fluorescent polyamides, and more specifically polyamides with a fluorescent label or reporter conjugated thereto. Such labels will fluoresce when bound to nucleic acids. Examples of polyamides with a fluorescent label or reporter attached thereto include, for example, those disclosed in Best et al., Proc. Natl. Acad. Sci. USA, 100(21): 12063-12068 (2003); Gygi, et al., Nucleic Acids Res., 30(13): 2790-2799 (2002); U.S. Pat. No. 5,998,140; U.S. Pat. No. 6,143,901; and U.S. Pat. No. 6,090,947, the contents of each of which is hereby incorporated herein by reference.
Fluorescent nucleotide sequences may also be used to label the sperm cells. Such nucleotide sequences fluoresce when hybridized to a nucleic acid containing a target or complementary sequence, but are otherwise non-fluorescent when in a non-hybridized state. Such oligonucleotides are disclosed, for example, in U.S. Patent Application Publication No. 2003/0113765 (hereby incorporated herein by reference).
Sex specific antibodies may also be used to label the sperm cells in a labeling mixture. In this embodiment, for example, a sex specific antibody may be conjugated with a fluorescent moiety (or equivalent reporter molecule). Because the antibody binds to antigens present on only an X chromosome-bearing or, alternatively, a Y chromosome-bearing cell, such cells can be selectively identified based upon their fluorescence (versus the non-fluorescence of an unlabeled cell). Moreover, more than one sex specific antibody, each antibody having a different fluorescent moiety attached thereto, may be used simultaneously. This allows for differentiation of X chromosome-bearing and Y chromosome-bearing cells based upon the differing fluorescence of each.
Luminescent, color-selective nanocrystals may also be used to label sperm cells in a labeling mixture. Also referred to as quantum dots, these particles are well known in the art, as demonstrated by U.S. Pat. No. 6,322,901 and U.S. Pat. No. 6,576,291, each of which is hereby incorporated herein by reference. These nanocrystals have been conjugated to a number of biological materials, including for example, peptides, antibodies, nucleic acids, streptavidin, and polysaccharides, (see, for example, U.S. Pat. Nos. 6,207,392; 6,423,551; 5,990,479, and 6,326,144, each of which is hereby incorporated herein by reference), and have been used to detect biological targets (see, for example, U.S. Pat. Nos. 6,207,392 and 6,247,323, each of which is hereby incorporated herein by reference).
The preferred concentration of the label in the labeling mixture is a function of a range of variables which include, for example, whether the label binds to the exterior of the cell or whether it must cross the cell membrane; if it must cross the cell membrane, the permeability of the cells to the selected label; the temperature of the labeling mixture; the amount of time allowed for labeling to occur; and the degree of selectivity desired. In general, the concentration of the label is preferably sufficient to achieve the desired degree of labeling of the cells in a reasonably short period of time without substantially detrimentally affecting sperm viability. For example, the concentration of Hoechst 33342, Hoechst 33258, SYBR-14, or BBC in the labeling mixture will generally be between about 0.1 μM and about 1.0M, preferably from about 0.1 μM to about 700 μM, and more preferably from about 100 μM to about 200 μM. In a particularly preferred embodiment, the concentration of Hoechst 33342, Hoechst 33258, SYBR-14, or BBC in the staining mixture will generally be between about 400 μM to about 500 μM, and most preferably about 450 μM. Accordingly, under one set of labeling conditions, the concentration of Hoechst 33342 is preferably about 100 μM. Under another set of labeling conditions, the concentration of Hoechst 33342 is about 150 μM. Under still another set of labeling conditions the concentration is preferably about 200 μM. Under yet another set of staining conditions the concentration of Hoechst 33342 is most preferably about 450 μM.
As another example, the concentration of a fluorescent polyamide, such as for example, those described in U.S. Application Publication No. 2001/0002314, will generally be between about 0.1 μM and about 1 mM, preferably from about 1 μM to about 1 mM, more preferably about 5 μM to about 100 μM, even more preferably about 10 μM.
Once formed, the labeling mixture may be maintained at any of a range of temperatures. For example, labeling with Hoechst 33342 or Hoechst 33258 typically will be performed within a range of about 4° C. to about 50° C. For example, the labeling mixture may be maintained at a “relatively low” temperature, i.e., a temperature of about 4° C. to about 30° C.; in this embodiment, the temperature is preferably from about 20° C. to about 30° C., more preferably from about 25° C. to about 30° C., and most preferable at about 28° C. Alternatively, the labeling mixture may be maintained within an “intermediate” temperature range, i.e., a temperature of about 30° C. to about 39° C.; in this embodiment, the temperature is preferably at about 34° C. to about 39° C., and more preferably about 37° C. In addition, the labeling mixture may be maintained within a “relatively high” temperature range, i.e., a temperature of about 40° C. to about 50° C.; in this embodiment, the temperature is preferably from about 40° C. to about 45° C., more preferably from about 40° C. to about 43° C., and most preferably at about 41° C. Selection of a preferred temperature generally depends upon a range of variables, including for example, whether the label binds to the exterior of the cell or whether it must cross the cell membrane; if it must cross the cell membrane, the permeability of the cells to the selected label; the concentration of the label(s) in the labeling mixture; the amount of time allowed for labeling to occur; and the degree of selectivity desired.
The pH of the labeling mixture may be maintained at any of a range of pH's. For example, labeling with Hoechst 33342 or Hoechst 33258 typically will be performed in a pH range of about 5.0 to about 9.0. For example, the labeling mixture may be maintained at a “slightly acidic” pH, i.e., from about 5.0 to about 7.0. In this embodiment, the pH is preferably from about 6.0 to about 7.0, more preferably from about 6.0 to about 6.5, and most preferably at about 6.2. Alternatively, the labeling mixture may be maintained at a “slightly basic” pH, i.e., from about 7.0 to about 9.0. In this embodiment, the pH is preferably from about 7.0 to about 8.0, more preferably from about 7.0 to about 7.5, and most preferably at about 7.3. Generally, however, if labeling is performed at a pH other than about 7.0, once a period of time sufficient to obtain the desired degree of labeling has occurred, the labeling mixture will be adjusted to a pH of about 7.0.
Optionally, the labeling mixture may also contain additives to enhance sperm viability. Exemplary additives include an antibiotic, a growth factor, or a composition which regulates oxidation/reduction reactions intracellularly and/or extracellularly as discussed above with respect to cell sample collection. These additives may be added to the labeling mixture in accordance therewith.
Uptake of the label by or binding of the label to the sperm cells in the labeling mixture is allowed to continue for a period of time sufficient to obtain a dispersion of sperm cells labeled to the desired degree. That period is typically a period sufficient for the label to bind to the sperm cells or the DNA of the sperm cells such that a member of a subpopulation of cells may be identified and its position in the dispersion determined. Selection of a preferred period generally depends upon a range of variables, including for example, whether the label binds to the exterior of the cell or whether it must cross the cell membrane; if it must cross the cell membrane, the permeability of the cells to the selected label; the concentration of the label(s) in the labeling mixture; the temperature of the labeling mixture; and the degree of selectivity desired. For example, the period may be a period sufficient for a fluorescent DNA selective dye to bind to the DNA of X and Y chromosome-bearing sperm cells such that they may be selected based upon the differing and measurable fluorescence intensity between the two. When, labeling with Hoechst 33342 or Hoechst 33258, for example, typically this period will be no more than about 160 minutes, preferably no more than about 90 minutes, still more preferably no more than about 60 minutes, and most preferably from about 5 minutes to about 40 minutes.
Certain labels, and in particular certain dyes, are capable of permeating the sperm cells and specifically binding the DNA without further intervention to increase the permeability of the cells. With other labels, however, it may be desirable to treat the sperm cells prior to labeling to increase the rate of permeation without unacceptably reducing viability or motility. Any suitable method known to those skilled in the art may be used. Such methods include electroporation, the use of cell-permeation-enhancing solutions, e.g., mild surfactants, or chemical shock. Where it is desired or advantageous to use other or more stringent techniques, such treatments can include the use of liposomes or many of the techniques which are used by those skilled in the art to introduce stains, dyes, genes, or vectors into living cells. These methods include, but are not limited to microinjection such as used by Gordon et al. (Proc. Natl. Acad. Sci. USA, 77(12): 7380-4 (1980)) and since extended to rabbits, sheep, cattle and pigs; DEAE-dextran-mediated transfer; coprecipitation with calcium phosphate; and other techniques, all of which are well known to one of skill in the art. In yet other instances, it may be desirable to centrifuge the sperm and re-suspend the centrifuged sperm in another medium, albeit based on the same or substantially the same buffer system, to remove certain components (which may have previously been added to the sperm dispersion) that may interfere with later processing steps.
One particularly preferred method of increasing the permeability of a sperm cell to a label is the well known method of optoinjection as disclosed in U.S. Pat. No. 6,753,161, the contents of which is hereby incorporated herein by reference. Generally, optoinjection is a method of transiently permeabilizing a cell by contacting the cell with a pulse of radiation. A cell is illuminated, identified and located based upon the detection of the illumination of the cell, and irradiated with a pulse of radiation sufficient to transiently permeabilize the cell. As applied to the present invention, for example, optoinjection may be used to transiently permeabilize sperm cells and thereby allow labels that bind to the internal contents of a cell (such as, for example, labels that bind to DNA or RNA) to more easily and efficiently enter into the cells. Therefore, optoinjection may be used, for example, to decrease the time needed to sufficiently label sperm cells with a fluorescent DNA selective dye, such as Hoechst 33342, Hoechst 33258, or with a fluorescent polyamide.
Optoinjection may also be used to label cells at reduced temperatures. Previously, sperm cells were generally labeled with, for example, fluorescent DNA selective dyes, at temperatures in excess of 30° C. and even 40° C., as the higher temperatures aided in increased dye uptake. While labeling at such temperatures is certainly feasible, it may be beneficial to avoid exposing the sperm cells to higher temperatures, especially for an extended period of time. Therefore, optoinjection may be used to permeabilize sperm cells, thereby allowing for the labeling of the cells at a lower temperature while still maintaining or exceeding the staining efficiency and speed typically associated with labeling at higher temperatures.
Accordingly, in one embodiment, a labeling mixture is formed comprising sperm cells, a motility inhibitor, and a dye in a concentration from about 100 μM to about 200 μM, and the staining mixture is held for a period of time at a temperature of about 41° C. In another embodiment, the motility inhibitor comprises 0.204 g NaHCO3, 0.433 g KHCO3, and 0.473 g C6H8O7.H2O per 25 mL of purified water (0.097 moles/L of NaHCO3, 0.173 moles/L of KHCO3, 0.090 moles/L C6H8O7.H2O in water).
In another embodiment, a labeling mixture is formed comprising sperm cells, a motility inhibitor, and a dye in a concentration of about 400 μM to about 500 μM, and the staining mixture is held for a period of time at a temperature of about 41° C. In another embodiment, the dye concentration is 450 μM. In another embodiment, the motility inhibitor comprises 0.204 g NaHCO3, 0.433 g KHCO3, and 0.473 g C6H8O7.H2O per 25 mL of purified water (0.097 moles/L of NaHCO3, 0.173 moles/L of KHCO3, 0.090 moles/L C6H8O7.H2O in water).
In still another embodiment, a labeling mixture is formed comprising sperm cells, a motility inhibitor, and a dye in a concentration from about 100 μM to about 200 μM, and the staining mixture is held for a period of time at a temperature of about 28° C. In another embodiment, the motility inhibitor comprises 0.204 g NaHCO3, 0.433 g KHCO3, and 0.473 g C6H8O7.H2O per 25 mL of purified water (0.097 moles/L of NaHCO3, 0.173 moles/L of KHCO3, 0.090 moles/L C6H8O7.H2O in water).
In yet another embodiment, a labeling mixture is formed comprising sperm cells, a motility inhibitor, and a dye in a concentration from about 400 μM to about 500 μM, and the staining mixture is held for a period of time at a temperature of about 28° C. In another embodiment, the dye concentration is 450 μM. In another embodiment, the motility inhibitor comprises 0.204 g NaHCO3, 0.433 g KHCO3, and 0.473 g C6H8O7.H2O per 25 mL of purified water (0.097 moles/L of NaHCO3, 0.173 moles/L of KHCO3, 0.090 moles/L C6H8O7.H2O in water).
Formation of a Dispersion of Labeled Cells
Once a labeling mixture is formed, the labeling mixture is used to form a dispersion of labeled cells, which is subsequently inspected and dosed. Such a dispersion comprises labeled sperm cells and a chemical agent that induces sperm immotility. Alternatively, or in addition to, the dispersion may comprise a liquid, such as a buffer as described above, in addition to the labeled sperm cells, and wherein the temperature of the cells or the liquid induces sperm immotility.
The labeled sperm cells may be in any of a number of forms. For example, the labeled cells may still be part of a labeling mixture. As such, the labeled cells may still be in excess or unbound label. Alternatively, the labeled cells may have been separated from any excess or unbound label, such as for example by washing the cells or by spinning down the cells, such as by centrifugation, and then separating the cells from the unbound label. In such an instance, the labeled cells will generally thereafter be combined with a buffer as discussed above with respect to collection of a cell sample. In any event, the sperm cells in the dispersion are labeled such that the absence or amount of label associated with one or more of the sperm cells allows for the identification of a genetic, proteomic, structural, or functional characteristic of a subpopulation of sperm cells in the dispersion. The sperm cells may be maintained at a temperature that induces or increases sperm immotility.
The dispersion of labeled cells may also contain a chemical agent that induces sperm immotility, such as, for example, a motility inhibitor as discussed above. The chemical agent may be added to the labeling mixture or labeled cells at any time before the optical inspection of the dispersion, such as for example, before, during, or after labeling of the sperm cells. The chemical agent may be combined with labeled cells, the labeled cells being in any of the number of forms discussed above (i.e., still in the labeling mixture or removed therefrom). In a particular embodiment, a labeling mixture is formed comprising sperm cells and a label, and then the labeling mixture is combined with the chemical agent that induces sperm immotility. Alternatively, or in addition to the chemical agent, the temperature of the labeling mixture may be reduced as discussed above in order to induce or increase sperm immotility.
Inspection, Determination, and Dosing of the Cells
Once a dispersion of labeled cells has been formed, the dispersion is optically inspected to identify individual sperm cells as members of a subpopulation, the positions of the members of the subpopulation in the dispersion are determined, and an energy beam is delivered to different positions within the dispersion to selectively dose members of the subpopulation with an energy source, thereby decreasing the viability of the dosed cells, or at least their capacity to fertilize an egg, without similarly affecting sperm cells at other positions in the dispersion.
These steps are typically performed by a device and in a manner commercially referred to as LEAP® (Laser-Enabled Analysis and Processing) Technology Platform (Cyntellect, Inc., San Diego, Calif.). Generally, this process requires that cells be labeled with a marker to identify and locate individual cells of a subpopulation of cells within a mixture or larger population of cells. The population of cells is then illuminated, allowing for the position of the individuals cells of the subpopulation to be identified. A treatment laser is then positioned in a manner such that it can emit a beam of energy to induce a change in the identified cells of the subpopulation. The induced change is usually cell death. These processes and devices are further described in U.S. Pat. Nos. 6,534,308; 6,514,722; 6,753,161; and 6,642,018, each of which is hereby incorporated herein by reference.
The energy source as used in the present invention may be any source that, when applied in a certain dose to the sperm cells, decreases the viability of the dosed cells, or at least their capacity to fertilize an egg, with minimal or no similar affect to sperm cells at other positions in the dispersion. Typically, the energy source will be in the form of an energy beam. Examples of suitable energy sources include lasers, collimated or focused non-laser light, RF energy, accelerated particles, focused ultrasonic energy, electron beams, or other radiation beams. Preferably, however, the energy source is a laser, as a laser provides the advantages of high intensity and relatively efficient use of energy in a compact size and with minimal heat generation, thereby allowing dosing of a single cell without significantly adversely affecting surrounding cells.
The cells may be placed on any surface suitable for optical inspection and dosing of the cells. Generally, such surfaces will have a horizontal surface (either a top, a bottom, or both) that is optically transparent to the energy source used to optically inspect the cells as well as the energy source used to dose members of the subpopulation. Such suitable surfaces include, for example, glass, plastics or other related polymers, and Pyrex®, and may be in the form of a flat slide, a petri dish, a single-well plate, or a multi-well plate. Examples are discussed in, for example, U.S. Pat. Nos. 6,534,308 and 6,514,722.
A sample of sperm cells may be divided into several smaller, individual samples, such as for example, by being divided into a number of individual samples for use with a multi-well plate. Each sample (for example, within each well) may be enriched for the same characteristic, thereby producing multiple samples each of which is enriched for a single characteristic. Advantageously, however, each of the samples may be enriched for a different characteristic. By way of example, a sample of sperm cells may be divided into smaller, individual samples, and each individual sample placed in one well of a 96 well plate. The individual sample of each well may then be enriched with respect to a single characteristic different from that of the samples in each of the other wells, resulting in 96 individual samples, each enriched with respect to a different characteristic.
Once the member cells of the subpopulation have been dosed with an energy source, the cell population may be further enriched by purifying the non-dosed cells (i.e., the sperm cells that were not dosed with energy). The purification of the non-dosed cells may occur by removal of either the dosed cells or the non-dosed cells from the dispersion, resulting in a subpopulation comprising non-dosed cells that are enriched for a particular characteristic. For example, if the particular characteristic is Y chromosome-bearing sperm cells, the non-dosed cells may be purified such that they comprise at least about 85% Y chromosome-bearing sperm cells; preferably at least about 90% Y chromosome-bearing sperm cells; more preferably at least about 95% Y chromosome-bearing sperm cells; even more preferably at least about 97% Y chromosome-bearing sperm cells; and most preferably at least about 99% Y chromosome-bearing sperm cells. Alternatively, if the particular desired characteristic is X chromosome-bearing sperm cells, the non-dosed cells may be purified such that they comprise at least about 85% X chromosome-bearing sperm cells; preferably at least about 90% X chromosome-bearing sperm cells; more preferably at least about 95% X chromosome-bearing sperm cells; even more preferably at least about 97% X chromosome-bearing sperm cells; and most preferably at least about 99% X chromosome-bearing sperm cells.
Removal of either the dosed or non-dosed cells from the dosed dispersion (i.e., from the larger population of sperm cells comprising both the dosed and non-dosed cells) may be achieved by any of a number of means known to those of skill in the art. Such methods include, for example, spinning down the entire dispersion, such as by centrifugation, and then removing or wicking the supernatant containing the dosed cells. Another method includes the addition of a high-density medium to the dispersion. High-density mediums that may be added to the dispersion include, for example, Percoll® and Isolate®. Generally, in a high-density separation, viable cells (i.e., non-dosed cells with respect to the present application) are able to swim to the top of the high-density medium and may thereafter be skimmed from the top of the medium, whereas damaged or dead cells (i.e., dosed cells) will remain dispersed within the high-density medium, generally within the bulk phase. Methods of using such mediums are well known in the art.
Advantageously, a dispersion of labeled cells may contain a subpopulation of cells labeled with different labels. Each label may identify a different genetic, proteomic, structural, or functional characteristic of a subpopulation of sperm cells in the dispersion. Moreover, each label may be individually detectible when bound to a sperm cell; that is to say, it is possible to separately detect the different labels. For example, the labels may each fluoresce at different wavelengths.
A different label may be added to the labeling mixture or to the dispersion of labeled cells. Alternatively, a different label may be added subsequent to any of the steps of inspection, determination, or dosing of the cells. Preferably, however, a different label will be added subsequent to the dosing of the dispersion. For example, once the members of a subpopulation of sperm cells have been dosed, the dosed dispersion (including both the dosed cells and the non-dosed cells) or a purified dosed dispersion (including only the non-dosed cells) may be labeled again, but with a different label, and the process of inspection, determination, and dosing of the cells may be repeated, generally as disclosed above, based upon the absence or amount of the different label associated with a sperm cell.
Generally, the different label may be used to identify an additional genetic, proteomic, structural, or functional characteristic of the non-dosed cells that may be different from the characteristic used to previously identify members of a subpopulation to which a dose of energy was delivered (i.e., that is different from the characteristic used to previously determine cells to be dosed or not dosed). This provides a manner of further enriching an already enriched population of cells.
By way of example, a dispersion of labeled cells may be formed using a fluorescent DNA selective dye. The dispersion may then be optically inspected to identify individual sperm cells that are X chromosome-bearing. The position of the X chromosome-bearing sperm cells may subsequently be determined, and a dose of energy may then be delivered to one or more of the X chromosome-bearing cells, thereby achieving an enriched Y chromosome-bearing viable cell population. Thereafter, the dosed dispersion (including both the dosed (X chromosome-bearing) and non-dosed (Y chromosome-bearing) cells) or a purified dosed dispersion (including only the non-dosed cells) may be labeled with another label that indicates acrosomal integrity, such as for example, phycoerythrin-conjugated peanut agglutinin (PE-PNA) that induces cell fluorescence, and in particular acrosomal fluorescence, when contacted with a cell having a reacted or damaged acrosome. The steps of optical identification and determination of the position of PE-PNA fluorescing cells may then be performed, and those cells dosed with energy. The result is a subpopulation of non-dosed cells that are Y chromosome-bearing and that have unreacted and undamaged (i.e., intact) acrosomes. See, for example, Nagy et al., Biol Reprod, 68: 1828-1835 (2003).
Cryoextension of the Cells
Once the member cells of the subpopulation have been dosed with an energy source, the entire sperm cell population (both dosed and non-dosed cells) or a subset of the population (the non-dosed cells only) may be cooled or frozen for use at a later date, for example, in fertilization procedures. In such instances, the non-dosed sperm calls may benefit from the addition of a cryoextender to minimize the impact upon viability or post-thaw motility as a result of cooling and freezing.
Generally, a cryoextender may comprise a protein source, a cryoprotectant, and a motility inhibitor. If included, a protein source may be added to provide support to the cells. The protein source may be any protein source that does not interfere with the viability of the non-dosed sperm cells and is compatible with the motility inhibitor. Examples of common protein sources include milk (including heat homogenized and skim), milk extract, egg yolk, egg yolk extract, soy protein and soy protein extract. Such proteins may be found in a concentration from about 10% (v/v) to about 30% (v/v), preferably from about 10% (v/v) to about 20% (v/v), and more preferably about 20% (v/v).
A cryoprotectant is preferably included in the cryoextender to lessen or prevent cold shock or to maintain fertility of the non-dosed sperm cells. Numerous cryoprotectants are known in the art. Selection of a cryoprotectant suitable for use with a given extender may vary, and depends upon the species from which the sperm to be frozen were obtained. Examples of suitable cryoprotectants include, for example, glycerol, dimethyl sulfoxide, ethylene glycol, propylene glycol, trehalose, Triladyl®, and combinations thereof. If included, generally, these cryoprotectants are present in the cryoextender in an amount of about 1% (v/v) to about 15% (v/v), preferably in an amount of about 5% (v/v) to about 10% (v/v), more preferably in an amount of about 7% (v/v), and most preferably in an amount of about 6% (v/v).
In addition, the cryoextender may contain a motility inhibitor as discussed above with respect to cell sample collection. The motility inhibitor(s) may be added to the cryoextender in accordance therewith.
In one particular embodiment, the cryoextender comprises a motility inhibitor, water, Triladyl®, egg yolk, and pyruvic acid. In yet another embodiment, the cryoextender comprises 0.097 moles/L of NaHCO3, 0.173 moles/L of KHCO3, 0.090 moles/L C6H8O7.H2O in water, and 25 g Triladyl®, 25 g egg yolk, and 10 mM pyruvic acid per 75 mL of water.
In another particular embodiment, the cryoextender comprises a motility inhibitor, water, Triladyl®, and egg yolk. In yet another embodiment, the cryoextender comprises 0.097 moles/L of NaHCO3, 0.173 moles/L of KHCO3, 0.090 moles/L C6H8O7.H2O in water, and 25 g Triladyl®, and 25 g egg yolk per 75 mL of water.
Optionally, the cryoextender may also contain an antibiotic or a composition which regulates oxidation/reduction reactions intracellularly and/or extracellularly as discussed above with respect to cell sample collection. Each of these additives may be added to the cryoextender in accordance therewith.
Cryopreservation of the entire sperm population (i.e., cryopreservation of the dosed dispersion) results in the formation of a frozen dispersion having two subpopulations, each of these subpopulations being substantially different from the other. However, each subpopulation is composed of substantially homogenous cells. That is to say, each subpopulation is comprised of cells, each of the individual cells of a single subpopulation having a characteristic common to each of the other cells in the same subpopulation. In a preferred embodiment, the dispersion is further enriched prior to cryopreservation by purifying the dispersion, based upon the presence or the absence of the common characteristic(s), according to methods described above.
Therefore, for example, the present process could be used to form a frozen sperm dispersion, the dispersion comprising a dosed subpopulation of cells, wherein all the cells of the dosed subpopulation are X chromosome-bearing cells, and a non-dosed subpopulation of cells, wherein all the cells of the non-dosed subpopulation are Y chromosome-bearing cells. According to this embodiment of the invention, the cells not receiving a dose of energy (i.e., the non-dosed Y chromosome-bearing cells) will comprise at least about 85% Y chromosome-bearing sperm cells; preferably at least about 90% Y chromosome-bearing sperm cells; more preferably at least about 95% Y chromosome-bearing sperm cells; even more preferably at least about 97% Y chromosome-bearing sperm cells; and most preferably at least about 99% Y chromosome-bearing sperm cells.
Alternatively, the present process could be used to form a frozen sperm dispersion, the dispersion comprising a dosed subpopulation of cells, wherein all the cells of the dosed subpopulation are Y chromosome-bearing cells, and a non-dosed subpopulation of cells, wherein all the cells of the non-dosed subpopulation are X chromosome-bearing cells. According to this embodiment of the invention, the non-dosed X chromosome-bearing cells will comprise at least about 85% X chromosome-bearing sperm cells; preferably at least about 90% X chromosome-bearing sperm cells; more preferably at least about 95% X chromosome-bearing sperm cells; even more preferably at least about 97% X chromosome-bearing sperm cells; and most preferably at least about 99% X chromosome-bearing sperm cells.
Fertilization
The present invention also provides for a novel process for fertilizing an egg or a female mammal, generally employing the novel process for selectively decreasing the viability of a subpopulation of sperm cells in a cell dispersion as described above.
Once the dosing of the dispersion of labeled cells has occurred, the dosed dispersion (comprising both the dosed and non-dosed cells) may be used to fertilize a female mammal. Fertilization may be performed according to any of a number of methods well known to those of skill in the art. These methods include, for example, microinjection, artificial insemination, and other methods well known to those of skill in the art. For example, a dosed dispersion comprising both the dosed and non-dosed cells, a purified dispersion comprising only the non-dosed cells, or a derivative of either may be used to inseminate a female mammal, such as for example, by artificial insemination.
Alternatively, once the dosing of the dispersion of labeled cells has occurred, the dispersion may be used to fertilize an egg, and more particularly, an egg in vitro. The fertilized egg may thereafter be introduced into the uterus of a female mammal by any of a number of means well known to those of skill in the art, such as for example embryo transplant. For example, a dosed dispersion, a purified dispersion, or a derivative of either may be used to fertilize an egg in vitro. Subsequently, the fertilized egg may be introduced into the uterus of a female mammal.
Fertilization of a female mammal or an egg in vitro using any of the aforementioned dispersions may occur shortly after dosing of the dispersion is complete, such as for example, within about 7 days, preferably within about 5 days, more preferably within about 3 days, still more preferably within about 2 days, and in a particular embodiment, within about 1 day after dosing of the dispersion is complete. In such an instance, generally the dispersion may not have been cryopreserved prior to fertilization of a female mammal or an egg in vitro (i.e., the dispersion is fresh or comprises fresh sperm cells); instead it may have been maintained in a motility inhibitor and/or may have been refrigerated at temperatures of about 2° C. to about 7° C., more preferably from about 3° C. to about 5° C., and most preferably at about 4° C. Alternatively, the dispersion may be cryopreserved and then thawed prior to fertilization of a female mammal or an egg in vitro (i.e., the dispersion is frozen/thawed or comprises frozen/thawed sperm cells). Typically, in such an instance, the cryopreserved dispersion will be thawed immediately before fertilization of a female mammal or an egg in vitro.
Having described the invention in detail, it will be apparent that modifications and variations are possible without departing from the scope of the invention defined in the appended claims.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US2005/026269 | 7/22/2005 | WO | 00 | 8/7/2007 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2006/012597 | 2/2/2006 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3005756 | Van Demark | Oct 1961 | A |
| 3499435 | Rockwell et al. | Mar 1970 | A |
| 3547526 | Devereux | Dec 1970 | A |
| 3644128 | Lipner | Feb 1972 | A |
| 3661460 | Elking et al. | May 1972 | A |
| 3687806 | Van den Bovenkamp | Aug 1972 | A |
| 3710933 | Fulwyler et al. | Jan 1973 | A |
| 3738759 | Dittrich et al. | Jun 1973 | A |
| 3756459 | Bannister | Sep 1973 | A |
| 3761187 | Dittrich et al. | Sep 1973 | A |
| 3761941 | Robertson | Sep 1973 | A |
| 3788744 | Friedman et al. | Jan 1974 | A |
| 3791384 | Richter | Feb 1974 | A |
| 3791517 | Friedman | Feb 1974 | A |
| 3810010 | Thom | May 1974 | A |
| 3816249 | Bhattacharya | Jun 1974 | A |
| 3826364 | Bonner et al. | Jul 1974 | A |
| 3829216 | Persidsky | Aug 1974 | A |
| 3833796 | Fetner et al. | Sep 1974 | A |
| 3877430 | Wieder | Apr 1975 | A |
| 3893766 | Hogg | Jul 1975 | A |
| 3894529 | Shrimpton | Jul 1975 | A |
| 3906929 | Augspurger | Sep 1975 | A |
| 3909744 | Wisner et al. | Sep 1975 | A |
| 3916143 | Farrell | Oct 1975 | A |
| 3944917 | Hogg et al. | Mar 1976 | A |
| 3947093 | Goshima et al. | Mar 1976 | A |
| 3960449 | Carleton et al. | Jun 1976 | A |
| 3963606 | Hogg | Jun 1976 | A |
| 3973003 | Colas | Aug 1976 | A |
| 3973196 | Hogg | Aug 1976 | A |
| RE29141 | Hogg | Feb 1977 | E |
| 4006360 | Mueller | Feb 1977 | A |
| 4007087 | Ericsson | Feb 1977 | A |
| 4009260 | Ericsson | Feb 1977 | A |
| 4014611 | Simpson et al. | Mar 1977 | A |
| 4056324 | Gohde | Nov 1977 | A |
| 4058732 | Wieder | Nov 1977 | A |
| 4067965 | Bhattacharya | Jan 1978 | A |
| 4070617 | Kachel et al. | Jan 1978 | A |
| 4083957 | Lang | Apr 1978 | A |
| 4085205 | Hancock | Apr 1978 | A |
| 4092229 | Bhattacharya | May 1978 | A |
| 4110604 | Haynes et al. | Aug 1978 | A |
| 4148718 | Fulwyler | Apr 1979 | A |
| 4155831 | Bhattacharya | May 1979 | A |
| 4162282 | Fulwyler et al. | Jul 1979 | A |
| 4175662 | Zold | Nov 1979 | A |
| 4178936 | Newcomb | Dec 1979 | A |
| 4179218 | Erdmann et al. | Dec 1979 | A |
| 4189236 | Hogg et al. | Feb 1980 | A |
| 4191749 | Bryant | Mar 1980 | A |
| 4200802 | Salzman et al. | Apr 1980 | A |
| 4225229 | Gohde | Sep 1980 | A |
| 4225405 | Lawson | Sep 1980 | A |
| 4230558 | Fulwyler | Oct 1980 | A |
| 4251733 | Hirlman, Jr. | Feb 1981 | A |
| 4255021 | Brunsden | Mar 1981 | A |
| 4263508 | Leary et al. | Apr 1981 | A |
| 4267268 | Nelson, Jr. | May 1981 | A |
| 4274408 | Nimrod | Jun 1981 | A |
| 4274740 | Eidenschink et al. | Jun 1981 | A |
| 4276139 | Lawson | Jun 1981 | A |
| 4302166 | Fulwyler et al. | Nov 1981 | A |
| 4317520 | Lombardo et al. | Mar 1982 | A |
| 4318480 | Lombardo et al. | Mar 1982 | A |
| 4318481 | Lombardo et al. | Mar 1982 | A |
| 4318482 | Barry et al. | Mar 1982 | A |
| 4325483 | Lombardo et al. | Apr 1982 | A |
| 4327177 | Shrimpton | Apr 1982 | A |
| 4339434 | Ericsson | Jul 1982 | A |
| 4341471 | Hogg et al. | Jul 1982 | A |
| 4348107 | Leif | Sep 1982 | A |
| 4350410 | Minott | Sep 1982 | A |
| 4352558 | Eisert | Oct 1982 | A |
| 4361400 | Gray et al. | Nov 1982 | A |
| 4362246 | Adair | Dec 1982 | A |
| 4367043 | Sweet et al. | Jan 1983 | A |
| 4395397 | Shapiro | Jul 1983 | A |
| 4395676 | Hollinger et al. | Jul 1983 | A |
| 4400764 | Kenyon | Aug 1983 | A |
| 4408877 | Lindmo et al. | Oct 1983 | A |
| 4422761 | Frommer | Dec 1983 | A |
| 4448767 | Bryant | May 1984 | A |
| 4474875 | Shrimpton | Oct 1984 | A |
| 4487320 | Auer | Dec 1984 | A |
| 4492436 | Bergmann | Jan 1985 | A |
| 4498766 | Unterleitner | Feb 1985 | A |
| 4501366 | Thompson | Feb 1985 | A |
| 4511661 | Goldberg | Apr 1985 | A |
| 4515274 | Hollinger et al. | May 1985 | A |
| 4523809 | Taboada et al. | Jun 1985 | A |
| 4538733 | Hoffman | Sep 1985 | A |
| 4545677 | Chupp | Oct 1985 | A |
| 4559309 | Evenson | Dec 1985 | A |
| 4573796 | Martin | Mar 1986 | A |
| 4585736 | Dolbeare et al. | Apr 1986 | A |
| 4598408 | O'Keefe | Jul 1986 | A |
| 4600302 | Sage, Jr. | Jul 1986 | A |
| 4605558 | Shrimpton | Aug 1986 | A |
| 4609286 | Sage, Jr. | Sep 1986 | A |
| 4629687 | Schindler et al. | Dec 1986 | A |
| 4631483 | Proni et al. | Dec 1986 | A |
| 4637691 | Uehara et al. | Jan 1987 | A |
| RE32350 | Bhattacharya | Feb 1987 | E |
| 4654025 | Cassou et al. | Mar 1987 | A |
| 4659185 | Aughton | Apr 1987 | A |
| 4660971 | Sage et al. | Apr 1987 | A |
| 4661913 | Wu et al. | Apr 1987 | A |
| 4662742 | Chupp | May 1987 | A |
| 4673288 | Thomas et al. | Jun 1987 | A |
| 4673289 | Gaucher | Jun 1987 | A |
| 4680258 | Hammerling et al. | Jul 1987 | A |
| 4683195 | Mullis et al. | Jul 1987 | A |
| 4683202 | Mullis | Jul 1987 | A |
| 4691829 | Auer | Sep 1987 | A |
| 4698142 | Muroi et al. | Oct 1987 | A |
| 4702598 | Böhmer | Oct 1987 | A |
| 4704891 | Recktenwald et al. | Nov 1987 | A |
| 4710635 | Chupp | Dec 1987 | A |
| 4714680 | Civin | Dec 1987 | A |
| 4737025 | Steen | Apr 1988 | A |
| 4744090 | Freiberg | May 1988 | A |
| 4749458 | Muroi et al. | Jun 1988 | A |
| 4752131 | Eisenlauer et al. | Jun 1988 | A |
| 4756427 | Gohde et al. | Jul 1988 | A |
| 4758729 | Monnin | Jul 1988 | A |
| 4764013 | Johnston | Aug 1988 | A |
| 4765737 | Harris et al. | Aug 1988 | A |
| 4770992 | den Engh et al. | Sep 1988 | A |
| 4778593 | Yamashita et al. | Oct 1988 | A |
| 4780406 | Dolbeare et al. | Oct 1988 | A |
| 4780451 | Donaldson | Oct 1988 | A |
| 4786165 | Yamamoto et al. | Nov 1988 | A |
| 4790653 | North, Jr. | Dec 1988 | A |
| 4794086 | Kasper et al. | Dec 1988 | A |
| 4796788 | Bond | Jan 1989 | A |
| 4818103 | Thomas et al. | Apr 1989 | A |
| 4831385 | Archer et al. | May 1989 | A |
| 4836038 | Baldwyn | Jun 1989 | A |
| 4845025 | Lary et al. | Jul 1989 | A |
| 4846785 | Cassou | Jul 1989 | A |
| 4867908 | Recktenwald et al. | Sep 1989 | A |
| 4871249 | Watson | Oct 1989 | A |
| 4876458 | Takeda et al. | Oct 1989 | A |
| 4877965 | Dandliker et al. | Oct 1989 | A |
| 4887721 | Martin et al. | Dec 1989 | A |
| 4915501 | Steen | Apr 1990 | A |
| 4936465 | Zold | Jun 1990 | A |
| 4942305 | Sommer | Jul 1990 | A |
| 4954715 | Zold | Sep 1990 | A |
| 4957363 | Takeda et al. | Sep 1990 | A |
| 4959354 | Barbetti | Sep 1990 | A |
| 4965204 | Civin | Oct 1990 | A |
| 4979093 | Laine et al. | Dec 1990 | A |
| 4980277 | Junilla | Dec 1990 | A |
| 4981580 | Auer | Jan 1991 | A |
| 4983038 | Ohki et al. | Jan 1991 | A |
| 4987539 | Moore et al. | Jan 1991 | A |
| 4988619 | Pinkel | Jan 1991 | A |
| 4989977 | North, Jr. | Feb 1991 | A |
| 4999283 | Zavos et al. | Mar 1991 | A |
| 5005981 | Schulte et al. | Apr 1991 | A |
| 5007732 | Ohki et al. | Apr 1991 | A |
| 5017497 | de Grooth | May 1991 | A |
| 5021244 | Spaulding | Jun 1991 | A |
| 5030002 | North, Jr. | Jul 1991 | A |
| 5034613 | Denk et al. | Jul 1991 | A |
| 5040890 | North, Jr. | Aug 1991 | A |
| 5043591 | Ludlow et al. | Aug 1991 | A |
| 5055393 | Kwoh et al. | Oct 1991 | A |
| 5057413 | Terstappen et al. | Oct 1991 | A |
| 5072382 | Kamentsky | Dec 1991 | A |
| 5076472 | Gross et al. | Dec 1991 | A |
| 5079959 | Miyake et al. | Jan 1992 | A |
| 5084004 | Ranoux | Jan 1992 | A |
| 5087295 | Gross et al. | Feb 1992 | A |
| 5088816 | Tomioka et al. | Feb 1992 | A |
| 5089714 | Ludlow et al. | Feb 1992 | A |
| 5098657 | Blackford et al. | Mar 1992 | A |
| 5101978 | Marcus | Apr 1992 | A |
| 5116125 | Rigler | May 1992 | A |
| 5127729 | Oetliker et al. | Jul 1992 | A |
| 5132548 | Borden et al. | Jul 1992 | A |
| 5135759 | Johnson | Aug 1992 | A |
| 5138181 | Lefevre et al. | Aug 1992 | A |
| 5142140 | Yamazaki et al. | Aug 1992 | A |
| 5142462 | Kashima | Aug 1992 | A |
| 5144224 | Larsen | Sep 1992 | A |
| 5150313 | Van den Engh et al. | Sep 1992 | A |
| 5158889 | Hirako et al. | Oct 1992 | A |
| 5159397 | Kosaka et al. | Oct 1992 | A |
| 5159403 | Kosaka | Oct 1992 | A |
| 5162306 | Donaldson | Nov 1992 | A |
| 5167926 | Kimura et al. | Dec 1992 | A |
| 5180065 | Touge et al. | Jan 1993 | A |
| 5182617 | Yoneyama et al. | Jan 1993 | A |
| 5195979 | Schinkel et al. | Mar 1993 | A |
| 5199576 | Corio et al. | Apr 1993 | A |
| 5204884 | Leary et al. | Apr 1993 | A |
| 5215376 | Schulte et al. | Jun 1993 | A |
| 5219729 | Hodgen | Jun 1993 | A |
| 5247339 | Ogino | Sep 1993 | A |
| 5259593 | Orme et al. | Nov 1993 | A |
| 5260764 | Fukuda et al. | Nov 1993 | A |
| 5274240 | Mathies et al. | Dec 1993 | A |
| 5275787 | Yuguchi et al. | Jan 1994 | A |
| 5298967 | Wells | Mar 1994 | A |
| 5315122 | Pinsky et al. | May 1994 | A |
| 5316540 | McMannis et al. | May 1994 | A |
| 5317162 | Pinsky et al. | May 1994 | A |
| 5336217 | Buys et al. | Aug 1994 | A |
| 5346990 | Spaulding | Sep 1994 | A |
| RE34782 | Dandliker et al. | Nov 1994 | E |
| 5359907 | Baker et al. | Nov 1994 | A |
| 5366888 | Fry et al. | Nov 1994 | A |
| 5367474 | Auer et al. | Nov 1994 | A |
| 5370842 | Miyazaki et al. | Dec 1994 | A |
| 5371585 | Morgan et al. | Dec 1994 | A |
| 5395588 | North, Jr. et al. | Mar 1995 | A |
| 5400179 | Ito | Mar 1995 | A |
| 5412466 | Ogino | May 1995 | A |
| 5437987 | Ten et al. | Aug 1995 | A |
| 5439362 | Spaulding | Aug 1995 | A |
| 5444527 | Kosaka | Aug 1995 | A |
| 5447841 | Gray et al. | Sep 1995 | A |
| 5447842 | Simons | Sep 1995 | A |
| 5452054 | Dewa et al. | Sep 1995 | A |
| 5457526 | Kosaka | Oct 1995 | A |
| 5461145 | Kudo et al. | Oct 1995 | A |
| 5464581 | Van den Engh | Nov 1995 | A |
| 5466572 | Sasaki et al. | Nov 1995 | A |
| 5467189 | Kreikebaum et al. | Nov 1995 | A |
| 5469375 | Kosaka | Nov 1995 | A |
| 5471294 | Ogino | Nov 1995 | A |
| 5471299 | Kaye et al. | Nov 1995 | A |
| 5475487 | Mariella, Jr. et al. | Dec 1995 | A |
| 5480774 | Hew et al. | Jan 1996 | A |
| 5480775 | Ito et al. | Jan 1996 | A |
| 5483469 | Van den Engh et al. | Jan 1996 | A |
| 5488469 | Yamamoto et al. | Jan 1996 | A |
| 5492534 | Atheyde | Feb 1996 | A |
| 5494795 | Guerry et al. | Feb 1996 | A |
| 5495719 | Gray, Jr. | Mar 1996 | A |
| 5496272 | Chung et al. | Mar 1996 | A |
| 5503994 | Shear et al. | Apr 1996 | A |
| 5514537 | Chandler | May 1996 | A |
| 5523573 | Hanninen et al. | Jun 1996 | A |
| 5532155 | Ranoux | Jul 1996 | A |
| 5547849 | Baer et al. | Aug 1996 | A |
| 5548395 | Kosaka | Aug 1996 | A |
| 5548661 | Price et al. | Aug 1996 | A |
| 5550058 | Corio et al. | Aug 1996 | A |
| 5556764 | Sizto et al. | Sep 1996 | A |
| 5558998 | Hammond et al. | Sep 1996 | A |
| 5559032 | Pomeroy et al. | Sep 1996 | A |
| 5578449 | Fr asch et al. | Nov 1996 | A |
| 5579159 | Ito | Nov 1996 | A |
| 5584982 | Dovichi et al. | Dec 1996 | A |
| 5589457 | Wiltbank | Dec 1996 | A |
| 5596401 | Kusuzawa | Jan 1997 | A |
| 5601234 | Larue | Feb 1997 | A |
| 5601235 | Booker et al. | Feb 1997 | A |
| 5601533 | Hancke et al. | Feb 1997 | A |
| 5602039 | Van den Engh | Feb 1997 | A |
| 5602349 | Van den Engh | Feb 1997 | A |
| 5608519 | Grouley et al. | Mar 1997 | A |
| 5620842 | Davis et al. | Apr 1997 | A |
| 5622820 | Rossi | Apr 1997 | A |
| 5627037 | Ward et al. | May 1997 | A |
| 5633503 | Kosaka | May 1997 | A |
| 5641457 | Vardanega | Jun 1997 | A |
| 5643796 | Van den Engh et al. | Jul 1997 | A |
| 5650847 | Maltsev et al. | Jul 1997 | A |
| 5658751 | Yue | Aug 1997 | A |
| 5660997 | Spaulding | Aug 1997 | A |
| 5663048 | Winkfein et al. | Sep 1997 | A |
| 5665315 | Robert et al. | Sep 1997 | A |
| 5672880 | Kain | Sep 1997 | A |
| 5674743 | Ulmer | Oct 1997 | A |
| 5675401 | Wangler et al. | Oct 1997 | A |
| 5682038 | Hoffman | Oct 1997 | A |
| 5684575 | Steen | Nov 1997 | A |
| 5687727 | Kraus et al. | Nov 1997 | A |
| 5690815 | Krasnoff et al. | Nov 1997 | A |
| 5690895 | Matsumoto et al. | Nov 1997 | A |
| 5691133 | Critser et al. | Nov 1997 | A |
| 5693534 | Alak et al. | Dec 1997 | A |
| 5696157 | Wang et al. | Dec 1997 | A |
| 5699152 | Fedor et al. | Dec 1997 | A |
| 5700692 | Sweet | Dec 1997 | A |
| 5701012 | Ho | Dec 1997 | A |
| 5707808 | Roslaniec et al. | Jan 1998 | A |
| 5708868 | Ishikawa | Jan 1998 | A |
| 5712807 | Bangham | Jan 1998 | A |
| 5719666 | Fukuda et al. | Feb 1998 | A |
| 5719667 | Miers | Feb 1998 | A |
| 5726009 | Connors et al. | Mar 1998 | A |
| 5726364 | Van den Engh | Mar 1998 | A |
| 5726751 | Altendorf et al. | Mar 1998 | A |
| 5730941 | Lefevre et al. | Mar 1998 | A |
| 5736330 | Fulton | Apr 1998 | A |
| 5739902 | Gjelsnes et al. | Apr 1998 | A |
| 5745308 | Spangenberg | Apr 1998 | A |
| 5747349 | den Engh et al. | May 1998 | A |
| 5759767 | Lakowicz et al. | Jun 1998 | A |
| 5777732 | Hanninen et al. | Jul 1998 | A |
| 5780230 | Li et al. | Jul 1998 | A |
| 5786560 | Tatah et al. | Jul 1998 | A |
| 5790692 | Price et al. | Aug 1998 | A |
| 5793485 | Gourley | Aug 1998 | A |
| 5793842 | Schloemer et al. | Aug 1998 | A |
| 5796112 | Ichie | Aug 1998 | A |
| 5798276 | Haugland | Aug 1998 | A |
| 5799830 | Carroll et al. | Sep 1998 | A |
| 5804436 | Okun et al. | Sep 1998 | A |
| 5815262 | Schrof et al. | Sep 1998 | A |
| 5819948 | Van den Engh | Oct 1998 | A |
| 5824269 | Kosaka et al. | Oct 1998 | A |
| 5831723 | Kubota et al. | Nov 1998 | A |
| 5835262 | Iketaki et al. | Nov 1998 | A |
| 5840504 | Blecher | Nov 1998 | A |
| 5844685 | Gontin | Dec 1998 | A |
| 5846737 | Kang | Dec 1998 | A |
| 5866344 | Georgiou | Feb 1999 | A |
| 5868767 | Farley et al. | Feb 1999 | A |
| 5872627 | Miers | Feb 1999 | A |
| 5873254 | Arav | Feb 1999 | A |
| 5874266 | Palsson | Feb 1999 | A |
| 5876942 | Cheng et al. | Mar 1999 | A |
| 5880457 | Tomiyama et al. | Mar 1999 | A |
| 5880474 | Norton et al. | Mar 1999 | A |
| 5883378 | Irish et al. | Mar 1999 | A |
| 5888730 | Gray et al. | Mar 1999 | A |
| 5891734 | Gill et al. | Apr 1999 | A |
| 5893843 | Rodrigues Claro | Apr 1999 | A |
| 5895764 | Sklar et al. | Apr 1999 | A |
| 5895922 | Ho | Apr 1999 | A |
| 6704313 | De Resende et al. | Apr 1999 | B1 |
| 5899848 | Haubrich | May 1999 | A |
| 5909278 | Deka et al. | Jun 1999 | A |
| 5912257 | Prasad et al. | Jun 1999 | A |
| 5916144 | Li et al. | Jun 1999 | A |
| 5916449 | Ellwart et al. | Jun 1999 | A |
| 5917733 | Bangham | Jun 1999 | A |
| 5919360 | Contaxis, III et al. | Jul 1999 | A |
| 5919621 | Brown | Jul 1999 | A |
| 5934885 | Farrell et al. | Aug 1999 | A |
| 5962238 | Sizto et al. | Oct 1999 | A |
| 5972710 | Weigl et al. | Oct 1999 | A |
| 5985216 | Rens | Nov 1999 | A |
| 5985538 | Stachecju | Nov 1999 | A |
| 5990479 | Weiss | Nov 1999 | A |
| 5991028 | Cabib et al. | Nov 1999 | A |
| 5998140 | Dervan | Dec 1999 | A |
| 5998212 | Corio et al. | Dec 1999 | A |
| 6002471 | Quake | Dec 1999 | A |
| 6003678 | Van den Engh | Dec 1999 | A |
| 6042025 | Crampton et al. | Mar 2000 | A |
| 6042249 | Spangenberg | Mar 2000 | A |
| 6050935 | Ranoux et al. | Apr 2000 | A |
| 6071689 | Seidel | Jun 2000 | A |
| 6079836 | Burr et al. | Jun 2000 | A |
| 6086574 | Carroll et al. | Jul 2000 | A |
| 6087352 | Trout | Jul 2000 | A |
| 6090947 | Dervan | Jul 2000 | A |
| 6097485 | Lievan | Aug 2000 | A |
| 6111398 | Graham | Aug 2000 | A |
| 6117068 | Gourley et al. | Sep 2000 | A |
| 6119465 | Mullens et al. | Sep 2000 | A |
| 6120735 | Zborowski et al. | Sep 2000 | A |
| 6128133 | Bergmann | Oct 2000 | A |
| 6130034 | Aitken | Oct 2000 | A |
| 6132961 | Gray et al. | Oct 2000 | A |
| 6133044 | Van den Engh | Oct 2000 | A |
| 6133995 | Kubota | Oct 2000 | A |
| 6139800 | Chandler | Oct 2000 | A |
| 6140121 | Ellington et al. | Oct 2000 | A |
| 6143535 | Paisson | Nov 2000 | A |
| 6143901 | Dervan | Nov 2000 | A |
| 6146837 | van de Winkel | Nov 2000 | A |
| 6149867 | Seidel | Nov 2000 | A |
| 6153373 | Benjamin et al. | Nov 2000 | A |
| 6154276 | Mariella, Jr. | Nov 2000 | A |
| 6175409 | Nielsen et al. | Jan 2001 | B1 |
| 6177277 | Soini | Jan 2001 | B1 |
| 6193647 | Beebe et al. | Feb 2001 | B1 |
| 6201628 | Basiji et al. | Mar 2001 | B1 |
| 6207392 | Weiss | Mar 2001 | B1 |
| 6208411 | Vaez-Iravani | Mar 2001 | B1 |
| 6211477 | Cardott et al. | Apr 2001 | B1 |
| 6214560 | Yguerabide et al. | Apr 2001 | B1 |
| 6221654 | Quake et al. | Apr 2001 | B1 |
| 6221671 | Groner et al. | Apr 2001 | B1 |
| 6238920 | Nagai et al. | May 2001 | B1 |
| 6247323 | Maeda | Jun 2001 | B1 |
| 6248590 | Malachowski | Jun 2001 | B1 |
| 6256096 | Johnson | Jul 2001 | B1 |
| 6263745 | Buchanan | Jul 2001 | B1 |
| 6283920 | Eberle et al. | Sep 2001 | B1 |
| 6296810 | Ulmer | Oct 2001 | B1 |
| 6309815 | Tash | Oct 2001 | B1 |
| 6316234 | Bova | Nov 2001 | B1 |
| 6317511 | Horiuchi | Nov 2001 | B1 |
| 6322901 | Bawendi | Nov 2001 | B1 |
| 6323632 | Husher et al. | Nov 2001 | B1 |
| 6326144 | Bawendi | Dec 2001 | B1 |
| 6328071 | Austin | Dec 2001 | B1 |
| 6329158 | Hoffman et al. | Dec 2001 | B1 |
| 6332540 | Paul et al. | Dec 2001 | B1 |
| 6357307 | Buchanan et al. | Mar 2002 | B2 |
| 6368786 | Saint-Ramon | Apr 2002 | B1 |
| 6372422 | Seidel | Apr 2002 | B1 |
| 6372506 | Norton | Apr 2002 | B1 |
| 6384951 | Basiji et al. | May 2002 | B1 |
| 6395305 | Buhr | May 2002 | B1 |
| 6400453 | Hansen | Jun 2002 | B1 |
| 6411835 | Modell et al. | Jun 2002 | B1 |
| 6411904 | Chandler | Jun 2002 | B1 |
| 6416190 | Grier | Jul 2002 | B1 |
| 6423505 | Davis | Jul 2002 | B1 |
| 6423551 | Weiss | Jul 2002 | B1 |
| 6432630 | Blankenstein | Aug 2002 | B1 |
| 6432638 | Dervan et al. | Aug 2002 | B2 |
| 6452372 | Husher et al. | Sep 2002 | B1 |
| 6454945 | Weigl et al. | Sep 2002 | B1 |
| 6456055 | Shinabe et al. | Sep 2002 | B2 |
| 6463314 | Haruna | Oct 2002 | B1 |
| 6465169 | Walderich et al. | Oct 2002 | B2 |
| 6473176 | Basiji et al. | Oct 2002 | B2 |
| 6482652 | Furlong et al. | Nov 2002 | B2 |
| 6489092 | Benjamin et al. | Dec 2002 | B1 |
| 6495333 | Willmann et al. | Dec 2002 | B1 |
| 6495366 | Briggs | Dec 2002 | B1 |
| 6503698 | Dobrinsky et al. | Jan 2003 | B1 |
| 6511853 | Kopf-Sill et al. | Jan 2003 | B1 |
| 6514722 | Palsson et al. | Feb 2003 | B2 |
| 6524860 | Seidel | Feb 2003 | B1 |
| 6528802 | Koenig et al. | Mar 2003 | B1 |
| 6534308 | Palsson et al. | Mar 2003 | B1 |
| 6537829 | Zarling et al. | Mar 2003 | B1 |
| 6540895 | Spence et al. | Apr 2003 | B1 |
| 6563583 | Ortyn et al. | May 2003 | B2 |
| 6569464 | Mukherjee et al. | May 2003 | B1 |
| 6576291 | Bawendi | Jun 2003 | B2 |
| 6577387 | Ross, III et al. | Jun 2003 | B2 |
| 6580504 | Ortyn et al. | Jun 2003 | B1 |
| 6587203 | Colon | Jul 2003 | B2 |
| 6589792 | Malachowski | Jul 2003 | B1 |
| 6590911 | Spinelli et al. | Jul 2003 | B1 |
| 6596143 | Wang et al. | Jul 2003 | B1 |
| 6596499 | Jalink | Jul 2003 | B2 |
| 6604435 | Buchanan et al. | Aug 2003 | B2 |
| 6613525 | Nelson et al. | Sep 2003 | B2 |
| 6617107 | Dean | Sep 2003 | B1 |
| 6618143 | Roche et al. | Sep 2003 | B2 |
| 6618679 | Loehrlein et al. | Sep 2003 | B2 |
| 6641708 | Becker et al. | Nov 2003 | B1 |
| 6642018 | Koller et al. | Nov 2003 | B1 |
| 6658357 | Chandler | Dec 2003 | B2 |
| 6664550 | Rader et al. | Dec 2003 | B2 |
| 6667830 | Iketaki et al. | Dec 2003 | B1 |
| 6671044 | Ortyn et al. | Dec 2003 | B2 |
| 6673095 | Nordquist | Jan 2004 | B2 |
| 6674525 | Bardell et al. | Jan 2004 | B2 |
| 6698627 | Garcia et al. | Mar 2004 | B2 |
| 6700130 | Fritz | Mar 2004 | B2 |
| 6703621 | Wolleschensky | Mar 2004 | B2 |
| 6706163 | Seul et al. | Mar 2004 | B2 |
| 6707555 | Kusuzawa et al. | Mar 2004 | B1 |
| 6713019 | Ozasa et al. | Mar 2004 | B2 |
| 6729369 | Neas et al. | May 2004 | B2 |
| 6746873 | Buchanan et al. | Jun 2004 | B1 |
| 6752298 | Garcia et al. | Jun 2004 | B2 |
| 6753161 | Koller et al. | Jun 2004 | B2 |
| 6761286 | Py et al. | Jul 2004 | B2 |
| 6761288 | Garcia | Jul 2004 | B2 |
| 6767706 | Quake | Jul 2004 | B2 |
| 6780377 | Hall et al. | Aug 2004 | B2 |
| 6782768 | Buchanan et al. | Aug 2004 | B2 |
| 6789706 | Abergel et al. | Sep 2004 | B2 |
| 6789750 | Heldt | Sep 2004 | B1 |
| 6793387 | Neas et al. | Sep 2004 | B1 |
| 6813017 | Hoffman et al. | Nov 2004 | B1 |
| 6819411 | Sharpe et al. | Nov 2004 | B1 |
| 6849394 | Rozeboom | Feb 2005 | B2 |
| 6849423 | Mutz et al. | Feb 2005 | B2 |
| 6861265 | Van den Engh | Mar 2005 | B1 |
| 6941005 | Lary et al. | Sep 2005 | B2 |
| 7015310 | Remington | Mar 2006 | B2 |
| 7094527 | Seidel et al. | Aug 2006 | B2 |
| 7105355 | Kurabayashi et al. | Sep 2006 | B2 |
| 7195920 | Seidel et al. | Mar 2007 | B2 |
| 7208265 | Schenk | Apr 2007 | B1 |
| 7221453 | Sharpe et al. | May 2007 | B2 |
| 7335507 | Anzar et al. | Feb 2008 | B2 |
| 20010006416 | Johnson | Jul 2001 | A1 |
| 20020047697 | Husher et al. | Apr 2002 | A1 |
| 20020058332 | Quake et al. | May 2002 | A1 |
| 20020064809 | Mutz et al. | May 2002 | A1 |
| 20020096123 | Whittier et al. | Jul 2002 | A1 |
| 20020115055 | Matta | Aug 2002 | A1 |
| 20020119558 | Seidel | Aug 2002 | A1 |
| 20020131957 | Gavin | Sep 2002 | A1 |
| 20020171827 | Van den Engh | Nov 2002 | A1 |
| 20020182590 | Strange et al. | Dec 2002 | A1 |
| 20020186375 | Asbury et al. | Dec 2002 | A1 |
| 20020186874 | Price et al. | Dec 2002 | A1 |
| 20020198928 | Bukshpan et al. | Dec 2002 | A1 |
| 20030048433 | Desjonqueres | Mar 2003 | A1 |
| 20030059764 | Ravkin et al. | Mar 2003 | A1 |
| 20030059945 | Dzekunov et al. | Mar 2003 | A1 |
| 20030078703 | Potts | Apr 2003 | A1 |
| 20030096405 | Takayama et al. | May 2003 | A1 |
| 20030098421 | Ho | May 2003 | A1 |
| 20030113765 | Dempcy | Jun 2003 | A1 |
| 20030119050 | Shai | Jun 2003 | A1 |
| 20030119206 | Shai | Jun 2003 | A1 |
| 20030129091 | Seidel et al. | Jul 2003 | A1 |
| 20030157475 | Schenk | Aug 2003 | A1 |
| 20030165812 | Takayama et al. | Sep 2003 | A1 |
| 20030175917 | Cumming | Sep 2003 | A1 |
| 20030175980 | Hayenga et al. | Sep 2003 | A1 |
| 20030190681 | Shai | Oct 2003 | A1 |
| 20030207461 | Bell et al. | Nov 2003 | A1 |
| 20030209059 | Kawano | Nov 2003 | A1 |
| 20040005582 | Shipwast | Jan 2004 | A1 |
| 20040031071 | Morris et al. | Feb 2004 | A1 |
| 20040034879 | Rothstein et al. | Feb 2004 | A1 |
| 20040049801 | Seidel | Mar 2004 | A1 |
| 20040053243 | Evans | Mar 2004 | A1 |
| 20040055030 | Maxwell et al. | Mar 2004 | A1 |
| 20040061070 | Hansen | Apr 2004 | A1 |
| 20040061853 | Blasenheim | Apr 2004 | A1 |
| 20040062685 | Norton et al. | Apr 2004 | A1 |
| 20040072278 | Chou et al. | Apr 2004 | A1 |
| 20040107150 | Neas et al. | Jun 2004 | A1 |
| 20040132001 | Seidel et al. | Jul 2004 | A1 |
| 20050003472 | Anzar et al. | Jan 2005 | A1 |
| 20050011582 | Haug | Jan 2005 | A1 |
| 20050064383 | Bashkin et al. | Mar 2005 | A1 |
| 20050112541 | Durack | May 2005 | A1 |
| 20050214733 | Graham | Sep 2005 | A1 |
| 20050244805 | Ludwig et al. | Nov 2005 | A1 |
| 20050282245 | Ludwig et al. | Dec 2005 | A1 |
| 20060118167 | Neas et al. | Jun 2006 | A1 |
| 20060147894 | Sowter | Jul 2006 | A1 |
| 20060203226 | Roche et al. | Sep 2006 | A1 |
| 20060263829 | Evans et al. | Nov 2006 | A1 |
| 20060281176 | Seidel et al. | Dec 2006 | A1 |
| 20070026378 | Schenk | Feb 2007 | A1 |
| 20070026379 | Seidel et al. | Feb 2007 | A1 |
| 20070042342 | Seidel et al. | Feb 2007 | A1 |
| 20070092860 | Schenk | Apr 2007 | A1 |
| 20070099171 | Schenk | May 2007 | A1 |
| 20070099260 | Seidel et al. | May 2007 | A1 |
| 20070117086 | Evans et al. | May 2007 | A1 |
| 20070123461 | Josephson | May 2007 | A1 |
| 20070248976 | Harding | Oct 2007 | A1 |
| Number | Date | Country |
|---|---|---|
| 9704313 | Jun 1999 | BR |
| 1029833 | Apr 1978 | CA |
| 1 250 808 | Mar 1989 | CA |
| 2113957 | Jan 1994 | CA |
| ZL 03109426.0 | Dec 2005 | CN |
| 0025296 | Mar 1981 | EP |
| 0 046 345 | Feb 1982 | EP |
| 0 068 404 | Jan 1983 | EP |
| 0 026 770 | Mar 1983 | EP |
| 0 029 662 | Feb 1984 | EP |
| 0 025 296 | May 1985 | EP |
| 0140616 | May 1985 | EP |
| 0 158 147 | Oct 1985 | EP |
| 0 160 201 | Nov 1985 | EP |
| 0 229 814 | Jul 1987 | EP |
| 0 246 604 | Nov 1987 | EP |
| 0288029 | Apr 1988 | EP |
| 0276166 | Jul 1988 | EP |
| 0 289 677 | Nov 1988 | EP |
| 0 316 173 | May 1989 | EP |
| 0 317 809 | May 1989 | EP |
| A-0 366794 | May 1990 | EP |
| 0 409 293 | Jan 1991 | EP |
| 0 461 618 | Dec 1991 | EP |
| 0 463 562 | Jan 1992 | EP |
| 0468100 | Jan 1992 | EP |
| 0474 187 | Mar 1992 | EP |
| 0 316 172 | Jul 1992 | EP |
| 0 316 171 | Sep 1992 | EP |
| 0570102 | Mar 1993 | EP |
| 0538786 | Apr 1993 | EP |
| 0 279 000 | Jul 1993 | EP |
| 0 553 951 | Aug 1993 | EP |
| 0 288 029 | Jan 1994 | EP |
| 0 381 694 | Jun 1994 | EP |
| 0 361 504 | Jul 1994 | EP |
| 606847 | Jul 1994 | EP |
| 0 289 200 | Aug 1994 | EP |
| 0 555 212 | Oct 1994 | EP |
| 0 361 503 | Nov 1994 | EP |
| 0 696 731 | Feb 1996 | EP |
| 0 705 978 | Apr 1996 | EP |
| 0 711 991 | May 1996 | EP |
| 0 471 758 | Sep 1996 | EP |
| 0 736 765 | Oct 1996 | EP |
| 0 545 284 | Feb 1997 | EP |
| 0 360 487 | Jul 1997 | EP |
| 0 412 431 | Oct 1997 | EP |
| 0 526 131 | Jan 1998 | EP |
| A-0 478155 | Jan 1998 | EP |
| 0 822 404 | Feb 1998 | EP |
| 0 822 401 | Apr 1998 | EP |
| 0 556 748 | Oct 1998 | EP |
| 0 430 402 | Jan 1999 | EP |
| 0 529 666 | Apr 2000 | EP |
| 0 994 342 | Apr 2000 | EP |
| 0 752 133 | Jun 2000 | EP |
| 1 018 644 | Jul 2000 | EP |
| 1 118 268 | Jul 2001 | EP |
| 1 147 774 | Oct 2001 | EP |
| 0 534 033 | Nov 2001 | EP |
| 0 925 494 | Dec 2001 | EP |
| 0 748 316 | May 2002 | EP |
| 0 662 124 | Jun 2002 | EP |
| 1 245 944 | Oct 2002 | EP |
| 1 249 502 | Oct 2002 | EP |
| 1250897 | Oct 2002 | EP |
| 1 380 304 | Jan 2004 | EP |
| 1 403 633 | Apr 2004 | EP |
| 1 100 400 | May 2004 | EP |
| 1 257 168 | Feb 2005 | EP |
| 1471019 | Apr 1977 | GB |
| 2 121 976 | Jan 1984 | GB |
| 2 122 369 | Jan 1984 | GB |
| 2 125 181 | Feb 1984 | GB |
| 2 136 561 | Sep 1984 | GB |
| 2 137 352 | Oct 1984 | GB |
| 2145112 | Feb 1985 | GB |
| 2 144 542 | Mar 1985 | GB |
| 2 153 521 | Aug 1985 | GB |
| 2 243 681 | Nov 1991 | GB |
| 2 360 360 | Sep 2001 | GB |
| 61139747 (A) | Jun 1986 | JP |
| 61159135 (A) | Jul 1986 | JP |
| 2024535 | Jan 1990 | JP |
| 4126064 (A) | Apr 1992 | JP |
| 4126065 (A) | Apr 1992 | JP |
| 4126066 (A) | Apr 1992 | JP |
| 4126079 (A) | Apr 1992 | JP |
| 4126080 (A) | Apr 1992 | JP |
| 4126081 (A) | Apr 1992 | JP |
| WO 8401265 | Apr 1984 | WO |
| WO 8504014 | Sep 1985 | WO |
| WO 8807198 | Sep 1988 | WO |
| WO 8904470 | May 1989 | WO |
| WO 8904471 | May 1989 | WO |
| WO 9013315 | Nov 1990 | WO |
| WO 9105236 | Apr 1991 | WO |
| WO 9208120 | May 1992 | WO |
| WO 9217288 | Oct 1992 | WO |
| WO 9310803 | Jun 1993 | WO |
| WO 9317322 | Sep 1993 | WO |
| WO 9422001 | Sep 1994 | WO |
| WO 9604542 | Feb 1996 | WO |
| WO 9612171 | Apr 1996 | WO |
| WO 9612172 | Apr 1996 | WO |
| WO 9612173 | Apr 1996 | WO |
| WO 9631764 | Oct 1996 | WO |
| WO 9633806 | Oct 1996 | WO |
| WO 9729354 | Aug 1997 | WO |
| WO 9730338 | Aug 1997 | WO |
| WO 9735189 | Sep 1997 | WO |
| WO 9743620 | Nov 1997 | WO |
| WO 8904472 | May 1998 | WO |
| WO 9834094 | Aug 1998 | WO |
| WO 9848259 | Oct 1998 | WO |
| WO 9857152 | Dec 1998 | WO |
| WO 9905504 | Feb 1999 | WO |
| 9933956 | Jul 1999 | WO |
| WO 9938883 | Aug 1999 | WO |
| WO 9942810 | Aug 1999 | WO |
| WO 9944035 | Sep 1999 | WO |
| WO 9944037 | Sep 1999 | WO |
| WO 9947906 | Sep 1999 | WO |
| WO 9960397 | Nov 1999 | WO |
| WO 9957955 | Nov 1999 | WO |
| WO 9961888 | Dec 1999 | WO |
| WO 0006193 | Feb 2000 | WO |
| WO 0012204 | Mar 2000 | WO |
| WO 0036396 | Jun 2000 | WO |
| WO 0049387 | Aug 2000 | WO |
| 0054026 | Sep 2000 | WO |
| WO 0056444 | Sep 2000 | WO |
| WO 0070080 | Nov 2000 | WO |
| WO 0128700 | Apr 2001 | WO |
| WO 0129538 | Apr 2001 | WO |
| 0137655 | May 2001 | WO |
| WO 0140765 | Jun 2001 | WO |
| WO 0140765 | Jun 2001 | WO |
| WO 0142757 | Jun 2001 | WO |
| 0151612 | Jul 2001 | WO |
| WO 0161313 | Aug 2001 | WO |
| 0168110 | Sep 2001 | WO |
| WO 0168226 | Sep 2001 | WO |
| WO 0171348 | Sep 2001 | WO |
| WO 0175161 | Oct 2001 | WO |
| WO 0175176 | Oct 2001 | WO |
| 0185913 | Nov 2001 | WO |
| WO 0102836 | Nov 2001 | WO |
| WO 0185913 | Nov 2001 | WO |
| WO 0185913 | Nov 2001 | WO |
| WO 0190295 | Nov 2001 | WO |
| WO 0195815 | Dec 2001 | WO |
| WO 0201189 | Jan 2002 | WO |
| WO 0204666 | Jan 2002 | WO |
| 0219594 | Mar 2002 | WO |
| WO 0219943 | Mar 2002 | WO |
| WO 0220850 | Mar 2002 | WO |
| WO 0221102 | Mar 2002 | WO |
| WO 0223163 | Mar 2002 | WO |
| WO 0225269 | Mar 2002 | WO |
| WO 0226114 | Apr 2002 | WO |
| WO 0228311 | Apr 2002 | WO |
| WO 0229106 A12 | Apr 2002 | WO |
| 0241906 | May 2002 | WO |
| 0243574 | May 2002 | WO |
| WO 0241906 | May 2002 | WO |
| WO 0243486 | Jun 2002 | WO |
| WO 0244319 | Jun 2002 | WO |
| WO 02052244 | Jul 2002 | WO |
| WO 02054044 | Jul 2002 | WO |
| WO 02057775 | Jul 2002 | WO |
| WO 02060880 | Aug 2002 | WO |
| WO03020877 | Aug 2002 | WO |
| 02077011 | Oct 2002 | WO |
| WO 02077637 | Oct 2002 | WO |
| WO 02092161 | Nov 2002 | WO |
| WO 02092247 | Nov 2002 | WO |
| WO 03008102 | Jan 2003 | WO |
| WO 03008937 | Jan 2003 | WO |
| WO 03012403 | Feb 2003 | WO |
| WO 03016875 | Feb 2003 | WO |
| WO 03056330 | Jul 2003 | WO |
| WO 03056335 | Jul 2003 | WO |
| WO 03072765 | Sep 2003 | WO |
| WO 03078065 | Sep 2003 | WO |
| WO 03078972 | Sep 2003 | WO |
| WO 04001401 | Dec 2003 | WO |
| WO 2004006916 | Jan 2004 | WO |
| WO 2004009237 | Jan 2004 | WO |
| WO 2004009237 | Jan 2004 | WO |
| WO 2004012837 | Feb 2004 | WO |
| WO 2004012837 | Feb 2004 | WO |
| WO 2004017041 | Feb 2004 | WO |
| WO 2004017041 | Feb 2004 | WO |
| WO 2004024227 | Mar 2004 | WO |
| WO 2004024227 | Mar 2004 | WO |
| WO 2004046712 | Jun 2004 | WO |
| WO 2004059282 | Jul 2004 | WO |
| 2004087177 | Oct 2004 | WO |
| 2004088283 | Oct 2004 | WO |
| WO 2004003697 | Oct 2004 | WO |
| WO 2004104178 | Dec 2004 | WO |
| WO 2004104178 | Dec 2004 | WO |
| WO 2005094852 | Oct 2005 | WO |
| WO 2005095590 | Oct 2005 | WO |
| WO 2005095960 | Oct 2005 | WO |
| WO 2006015056 | Feb 2006 | WO |
| WO 2006012597 | Feb 2006 | WO |
| WO 2006060770 | Aug 2006 | WO |
| WO 2007016090 | Feb 2007 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20080039680 A1 | Feb 2008 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60590270 | Jul 2004 | US | |
| 60590769 | Jul 2004 | US | |
| 60614178 | Sep 2004 | US | |
| 60618440 | Oct 2004 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11092313 | Mar 2005 | US |
| Child | 11572376 | US | |
| Parent | 11092338 | Mar 2005 | US |
| Child | 11092313 | US | |
| Parent | 11092509 | Mar 2005 | US |
| Child | 11092338 | US |
